



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Large animal models of cardiovascular disease

**Citation for published version:**

Tsang, H-G, Rashdan, N, Whitelaw, C, Corcoran, B, Summers, K & MacRae, V 2016, 'Large animal models of cardiovascular disease', *Cell Biochemistry and Function*, vol. 34, no. 3, pp. 113–132.  
<https://doi.org/10.1002/cbf.3173>

**Digital Object Identifier (DOI):**

[10.1002/cbf.3173](https://doi.org/10.1002/cbf.3173)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Cell Biochemistry and Function

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## Large animal models of cardiovascular disease

H. G. Tsang<sup>1</sup>, N. A. Rashdan<sup>1</sup>, C. B. A. Whitelaw<sup>1</sup>, B. M. Corcoran<sup>2</sup>, K. M. Summers<sup>1</sup> and V. E. MacRae<sup>1\*</sup>

<sup>1</sup>The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Midlothian, SCT, UK

<sup>2</sup>Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Midlothian, SCT, UK

The human cardiovascular system is a complex arrangement of specialized structures with distinct functions. The molecular landscape, including the genome, transcriptome and proteome, is pivotal to the biological complexity of both normal and abnormal mammalian processes. Despite our advancing knowledge and understanding of cardiovascular disease (CVD) through the principal use of rodent models, this continues to be an increasing issue in today's world. For instance, as the ageing population increases, so does the incidence of heart valve dysfunction. This may be because of changes in molecular composition and structure of the extracellular matrix, or from the pathological process of vascular calcification in which bone-formation related factors cause ectopic mineralization. However, significant differences between mice and men exist in terms of cardiovascular anatomy, physiology and pathology. In contrast, large animal models can show considerably greater similarity to humans. Furthermore, precise and efficient genome editing techniques enable the generation of tailored models for translational research. These novel systems provide a huge potential for large animal models to investigate the regulatory factors and molecular pathways that contribute to CVD *in vivo*. In turn, this will help bridge the gap between basic science and clinical applications by facilitating the refinement of therapies for cardiovascular disease. 2016 The Authors. Published by John Wiley & Sons Ltd.

**KEY WORDS**—cardiovascular disease; large animal models; calcific aortic valve disease; aortic stenosis; vascular calcification; Marfan syndrome; genetic engineering

### INTRODUCTION

The mammalian cardiovascular system is a vast network of specialized structures and vessels, which allows blood and other important molecules to be transported throughout the body. Central to the system is the four-chambered heart that acts as a muscular pump to permit the movement of blood. Four cardiac valves ensure that blood flows through the heart and into the arteries in only one direction<sup>1</sup>. The veins and arteries comprise three concentric tubes: an outer connective tissue layer (tunica externa), a middle smooth muscle cell layer (tunica media), which is thinner in the veins than the arteries and an inner endothelial cell layer (tunica intima)<sup>2</sup>.

Cardiovascular disease (CVD) is a leading global cause of morbidity and mortality<sup>3</sup>. The American Heart Association (AHA) reported that CVD accounted for approximately one in three deaths in the United States in 2011<sup>4</sup>. Additionally, 34% of CVD-attributed deaths occurred before 75 years of age, which was below the present average life expectancy of 78.7 years<sup>4</sup>. According to the World Health Organization (WHO), some of the top cardiovascular-related causes of

premature death include coronary heart disease, chronic obstructive pulmonary disease, and stroke<sup>5</sup>.

In recent decades, both invasive and non-invasive therapies of CVD have advanced considerably. This advancement has been facilitated by basic research, and progressed with clinical studies<sup>6</sup>. Nowadays, it is becoming more apparent that understanding biological systems at the basic scientific level is important in order to provide clinicians with new approaches and tools for the assessment and treatment of their patients<sup>6</sup>.

Within the field of cardiovascular research, new interventional strategies range from experimental procedures for testing new implantations and devices, to more specific studies of underlying mechanisms of particular CVDs. In the development of these strategies and basic research, the role of animal models of CVD is especially important. This review aims to look at some of the cardiovascular issues in today's world, such as heart valve disease and vascular calcification, the expanding research resources made available through the use of large animal models and the potential of novel genetic engineering technologies in this field.

### ANIMAL MODELS OF CVDS

Animal models are important for discerning the aetiology and pathogenesis of human diseases with the purpose of developing novel disease preventions and therapies<sup>7</sup>. Many of

\*Correspondence to: Vicky MacRae, The Roslin Institute and Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, UK. E-mail: vicky.macrae@roslin.ed.ac.uk

our achievements on the treatment and management of CVDs have been made through the use of experimental animal models. These disease models have helped in outlining the pathogenesis, progression and mechanisms behind CVDs at the molecular and cellular levels, enabling the development of many effective treatment approaches.

A number of models exist to address cardiovascular complications, such as atherosclerosis and other cardiac diseases, where similar pathologies have been recreated in different species, including large and small animals. Although no model can entirely replicate the complexities seen in human pathologies, they are crucial in assessing mechanisms of disease, as well as evaluating novel diagnostic technologies, preventions and therapies<sup>7,8</sup>. Model organisms are used predominantly to improve human health, and to enable translatable scientific discoveries with practical applications. Large animals can facilitate in these goals, as they exhibit disease characteristics similar to humans, giving mechanistic insight into the biological and pathological processes. Additionally, they enable us to obtain direct information about specific physiological events, and studies of diseases with respect to a control group are possible in order to observe the effects of particular variables, treatments, and modified factors. This is in contrast to human studies, in which appropriate age and sex matched control sample groups are often very difficult to obtain.

The current use of small rodents as the main model of human diseases is widespread, and they are a popular choice of species for several reasons. They are relatively cost effective and easy to maintain, and can provide large litters; thus, studies can be given adequate power by the use of appropriate numbers of animals. The ability to genetically modify mice through either the ablation or overexpression of a gene of interest has made them indispensable in teasing apart the mechanisms underpinning CVD.

Nonetheless, limitations do exist, and significant cardiovascular differences are apparent between humans and rodents<sup>9</sup>. In light of the important role of inflammation in several CVDs, differences between species should be considered. One of the most drastic disparities between humans and mice is the response to bacterial lipopolysaccharides, which is five orders of magnitude higher in humans<sup>10</sup>. This contrasting response has been attributed to the differential composition of mouse serum<sup>11</sup>: in mouse blood the predominant population of leukocytes is lymphocytes, whereas human blood is neutrophil rich<sup>12</sup>. Interestingly, pigs show greater similarity to humans in this regard, whereby neutrophils are also the predominant circulating blood cell population<sup>13</sup>. Furthermore, during delayed-type hypersensitivity testing neutrophils surround the antigen followed by an influx of mononuclear cells resulting in a predominantly macrophage and T-cell lesion in humans<sup>14</sup>. However, in mice a comparable test results in a predominantly neutrophil lesion<sup>15</sup>. The small size of rodents makes them easy to handle and offers key advantages such as the application of intra vital microscopy in *in vivo* inflammatory studies<sup>16</sup>. Additional imaging techniques are frequently complicated by the smaller size, and smaller volumes of circulating blood also make repeat sampling challenging in these studies.

Although employing large animals may involve higher costs, because of their size and husbandry needs when compared to smaller models, their importance in the field of human diseases is evident as they have more cardiovascular similarities in terms of anatomy, physiology and size to humans than the rodent species. The ability to apply human-like settings to model animals increases the chances of bench findings translating to effective treatments. This includes using human clinical equipment and surgical techniques. For example pigs have been used for decades to develop surgical procedures for implementation in humans, and pig valves are used in some cases of human valve failure<sup>17</sup>. In addition, their larger size provides a better choice for imaging and tissue engineering studies. Studies utilising large animal models can illuminate the biological pathways and mechanisms to facilitate the refinement of CVD therapies. Despite these advantages, there are significant challenges to the use of large animal models in addition to costs. These include the availability of antibodies and assays specific to these species. However, with increasing use of large animals the increased demand should bring about an increase in availability of these products. Compared to the mouse there are few transgenic large animals. However, new gene editing technologies allow the establishment of precise and efficient gene editing techniques that, as described later in this review, should enable the generation of tailored large animal models of human disease.

## THE CARDIOVASCULAR SYSTEM, DISEASES AND INSIGHTS

### *Valvular heart disease (VHD)*

Valvular heart disease (VHD) encompasses a range of cardiovascular conditions, accounting for 10–20% of all cardiac surgeries in the United States<sup>18</sup>. As the ageing population continues to increase, so does the prevalence of patients with degenerative valve disorders<sup>4</sup>. In addition, the morbidity and mortality rates of open-heart surgery, the main approach taken for patients with VHD, can be high, providing challenges to reconstructive procedures<sup>6</sup>. Better understanding of the function of the valves and the perturbations that lead to disease is imperative to the future provision of surgical and therapeutic interventions.

There are four cardiac valves: the mitral (bicuspid) valve and aortic semilunar valve on the left side of the heart, and the tricuspid valve and pulmonary semilunar valve on the right side. The heart valve leaflet structure consists of cellular and extracellular components. Extracellular components include collagen, glycosaminoglycans (GAGs) and elastin present in the three layers of the valve: the fibrosa, spongiosa and ventricularis, respectively (Figure 1)<sup>19–22</sup>. Valve surface endothelial cells (VECs) and the inner valve interstitial cells (VICs) are the principal cell types found in the cardiac valves<sup>19,20,23</sup>.

Over 60% of valve disease mortality is because of semilunar valve dysfunction, especially of the aortic valve, with approximately 50 000 valve replacement or repair procedures reported each year in the USA<sup>24</sup>. Semilunar valve




Figure 1. Simplified cross section of the aortic valve showing progression of aortic valve calcification. Valve endothelial cells (VECs) line the valve leaflet surface. The inner layers of the valve consist of the fibrosa, spongiosa and ventricularis. The principal cell type within each layer is the valve interstitial cells (VICs). The fibrosa contains collagen (Types I and III), the spongiosa contains glycosaminoglycans (GAGs) and the ventricularis—elastin fibres. In calcific aortic valve disease (CAVD), often the fibrosa layer becomes calcified and thickened. This may be because of lipid deposition and inflammatory processes which trigger the osteochondrogenic transdifferentiation of VICs. Calcium deposition then occurs, forming bone-like material as neovascularization around the calcified lesions and remodelling of the extracellular matrix occurs. This results in the formation of calcified nodules and the thickening of the valve leaflet




Figure 2. Simplified diagram showing potential RANK/RANKL/OPG involvement in bone remodelling and in vascular calcification. Receptor activator of nuclear factor kappa-B ligand (RANKL) from osteoblasts or endothelial cells binds to the Receptor Activator of Nuclear Factor kappa-B (RANK) of osteoclast precursors, or vascular smooth muscle cells (VSMCs). This leads to differentiation into mature osteoclasts in the bone, which are involved in bone resorption, whereas in vascular calcification, VSMCs undergo a phenotypic transition into osteochondrogenic cells that can deposit mineralized matrix. Osteoprotegerin (OPG) is the decoy receptor for RANKL, and a potential inhibitor for mineralization

diseases affect all ages, from congenital valve defects in neonates and children, to the increasing number of elderly with calcified valves<sup>24</sup>. These dysfunctional heart valves most often require surgical replacement using mechanical or bioprosthetic valves which are prone to failure over time from structural or thrombosis-related problems<sup>24</sup>.

Although many studies into valvular biology use adult aortic valve tissues and cells from either humans or animals, it is clear that the subject's age is important in order to assess age-specific pathologies and conditions<sup>24</sup>. An earlier study reported numerous age-related changes in the extracellular matrix (ECM) composition and mechanical properties of the aortic valves, in addition to valve cell phenotypes<sup>24</sup>. The ECM is the cell-synthesized structural backbone of connective tissue. It provides a structural frame for mesenchyme-derived tissues, in addition to regulating interactions between numerous growth factors and cell surface

receptors<sup>25,26</sup>. Within the ECM are elastic fibres, collagen fibrils and microfibrils, which contain components including elastin, collagen and the fibrillins<sup>27</sup>. In the cardiovascular system, this complex meshwork also ensures normal cardiovascular function by providing the biomechanical characteristics of the blood vessel walls<sup>27</sup>. Substantial tissue growth and remodelling occur before adulthood<sup>24</sup>. In foetal development, trilaminar ECM structures or highly aligned elastin and collagen that are evident in adult valves are not yet present in the aortic valves<sup>24</sup>. The ECM is also an essential component in the cardiac valves, where its disruption has been reported in valve diseases, as will be mentioned later on. As valvular diseases continue to increase in the elderly population, improving our understanding of how valve cells and the ECM functions change throughout ageing is crucial, as well as distinguishing their responses to surrounding environments in various physiological states, such as those pertaining to vascular calcification.



The function of the cardiac valves is of crucial importance. However, the aortic valve is especially vital as it is a partition between the left ventricle and the aorta, at the level where the coronary arteries arise. Therefore, significant clinical complications occur when congenital defects and chronic disorders relating to the aortic valve are present, as current diagnostic and therapeutic strategies are inadequate. Although there have been major advancements in the last decade or so in valvular biology, there are still many pieces to be found to form a clear picture of the pathological mechanisms that impair valvular function.

### Models of calcific aortic valve disease (CAVD)

Calcific aortic valve disease (CAVD) is a progressive disorder involving valve leaflet thickening (aortic sclerosis), leading to severe calcification with impaired leaflet motion (aortic stenosis)<sup>28</sup>. Aortic stenosis is a major form of CVD, along with hypertension and coronary artery disease, in the Western world<sup>18,29</sup>. Almost 30% of adults above 65 years have aortic stenosis, and approximately 50% in those above 85 years<sup>30,31</sup>. It develops from progressive leaflet calcification, causing gradual restriction of the opening of the leaflets<sup>18</sup>. Aortic stenosis shares similarities with atherosclerosis, for example, their risk factors include age, diabetes, hypertension, obesity, increased low-density lipoprotein (LDL) cholesterol and lipoprotein(a), as well as smoking<sup>18,31–34</sup>. Pathological studies of human aortic stenosis have identified valvular lesions containing inflammatory cells and calcific deposits similar to those found in atherosclerotic plaques<sup>33</sup>. Once symptoms develop as a result of increasing stenosis severity, including angina and heart failure, there is a higher risk of sudden death with the average survival of only 2–3 years<sup>18,35</sup>.

Studies assessing the biological and structural changes in aortic valves have predominantly used mouse models. Techniques used have included staining for calcium deposition, quantitative real-time PCR (qRT-PCR) to examine changes in mRNA levels for specific genes, protein quantification and enzymatic activity<sup>36</sup>. To date, there are reports of pro-osteogenic signalling cascades thought to contribute to the initiation and progression of aortic stenosis. Signalling molecules include bone morphogenetic proteins (BMPs), Wnt/ $\beta$ -catenin and transforming growth factor- $\beta$  (TGF- $\beta$ ) although the role of TGF- $\beta$  in osteogenic signalling is not

clear<sup>36</sup>. The RANK/RANKL/OPG pathway is also thought to be involved in the calcification process, which involves complex interactions between receptor activator of nuclear factor kappa B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) (Figure 2)<sup>36,37</sup>. Matrix remodelling may also be involved in the expansion of calcified plaques and pro-inflammatory processes, through alterations in matrix metalloproteinases (MMPs) and elastin fragments produced by cathepsins<sup>36</sup>. Furthermore, the NOTCH1 pathway has been implicated as a regulator of valve calcification, through the repression of the osteoblast transcription factor Runt-related transcription factor 2 (RUNX2) (Figure 3)<sup>38</sup>. This suggests an inhibitory role of NOTCH1 in valvular calcification. Additionally, a number of ECM proteins have been found to have roles in CAVD including collagen, elastin and GAGs, where changes in their expression have impacts on cellular processes, and also cause valve leaflet thickening<sup>39</sup>.

Pro-mineralization processes can also be regulated by circulating calcification inhibitors, including matrix  $\gamma$ -carboxyglutamic acid or matrix Gla protein (MGP), which inhibits BMP signalling<sup>40</sup>. CAVD patients were also found to have less circulating MGP<sup>41</sup>. Another circulating inhibitor of calcification, Fetuin-A, binds clusters of calcium and phosphate, preventing their uptake into cells<sup>42</sup>. Circulating levels of Fetuin-A have been shown to be reduced in peritoneal dialysis patients displaying rapid development of valvular calcification<sup>43</sup>. Furthermore a cross-sectional study of 970 patients with coronary artery disease found an inverse relationship between circulating Fetuin-A levels and mitral and aortic valve calcification<sup>44</sup>. Aortic stenosis in patients with CAVD has also been associated with increased plasma levels of potential promoters of calcification, such as the non-collagenous bone matrix protein osteopontin (OPN), a pro-inflammatory glycoprotein that regulates calcium deposition by osteoblasts<sup>45</sup>.

The mechanism for CAVD development is similar to skeletal bone formation (ossification). CAVD progression is regulated by cells within the valve that develop an osteoblast-like phenotype<sup>46</sup>. Within calcified aortic valves, markers of bone differentiation have also been discovered, including RUNX2, OPN, osteocalcin (OCN) and bone sialoprotein<sup>46,47</sup>. RUNX2 expression is a marker for osteoblast differentiation, whilst OCN is a late marker of calcification in osteoblastogenesis<sup>48,49</sup>. Intriguingly, ossification, the




Figure 3. Simplified diagram showing potential NOTCH1 involvement in vascular calcification. NOTCH1 signalling may be involved in the inhibition, as well as the promotion, of vascular calcification through additional factors. Black arrows indicate stimulatory effects, whilst red lines indicate inhibitory effects

active process of bone tissue repair and remodelling, is observed in end-stage VHD<sup>50</sup>. In addition to the presence of mature lamellar bone and infiltration of inflammatory cells, BMPs -2 and -4 have been found in calcified valves<sup>50</sup>. BMP-2 is a potent osteogenic differentiation marker, a member of the TGF- $\beta$  superfamily, and has been found to be involved in calcification following the repression of NOTCH1 signalling in sheep aortic VICs<sup>51</sup>. Mutations in *NOTCH1* have been linked with the presence of aortic valve calcification in human and mouse studies, although the disease was much milder in the latter<sup>51</sup>. A recent study of NOTCH1 in human aortic VECs found that this factor positively regulated MGP<sup>52</sup>. Shear stress was simulated by media flow conditions *in vitro* and was found to activate *NOTCH1* expression<sup>52</sup>. Because MGP can inhibit BMPs, this may be the route through which NOTCH1 represses BMP-2. Intriguingly, it has been reported that NOTCH1 induces the differentiation and calcification of vascular smooth muscle cells (VSMCs) through a BMP-2 driven mechanism (Figure 3)<sup>51</sup>. However, the role of NOTCH1 in the calcification of valves and vessels remains to be fully understood, and requires further investigation.

The mechanisms underpinning the process of valvular calcification have yet to be fully elucidated. However, an 'initiation' and 'propagation' phase has been described<sup>53</sup>. It may be that in response to valvular damage, such as through endothelial disruption via shear stress, lipid deposition and inflammation occur, which subsequently triggers calcification (Figure 1)<sup>54–56</sup>. Neovascularization was also found in calcified valves, suggesting that this is important in CAVD<sup>50</sup>, with new vessels commonly found in areas of inflammation around calcified deposits<sup>57</sup>. Haemorrhage has been associated with neoangiogenesis, macrophage infiltration and accelerated disease progression in patients with advanced aortic stenosis<sup>58</sup>. Nevertheless, the roles of the factors and pathways involved in VHDs and other CVDs, including those briefly mentioned above, remain unclear. More information into the early stages of disease initiation and progression is required to understand the mechanisms of CAVD.

Currently, the only option to treat CAVD is through valve replacement surgery. This reflects our lack of understanding of the early pathobiological processes, even though later stages of the disease are well described. Additionally, as the implicated regulators of ectopic calcification are required for normal bone mineralization, establishing a therapeutic strategy that does not affect bone is crucial. And so, uncovering the factors and mechanisms that are important during the initiation and progression of these diseases facilitated by animal models is required for developing such treatments and interventions. Many studies into aortic stenosis utilize the mouse as a model<sup>36</sup>. However, the size of the aortic valves limits the amount of material available for examining the molecular mechanisms behind CAVD. Although diseased human valve samples can be obtained relatively easily, acquiring healthy samples is nearly impossible. In contrast, healthy valve samples from animals are far more accessible, can be used as a healthy control and can

provide a source of valve cells that can be isolated for experimentation<sup>59,60</sup>.

#### *Large animal models of cardiovascular dysfunction.*

Models of CAVDs (Table 1) have been established in a range of animals including the pig, rabbit and dog (reviewed in<sup>61–66</sup>). For cardiac valve specific studies, aortic valve cells, predominantly the VECs and VICs, have been isolated and cultured from various large animals, including the pig, cow, sheep and dog<sup>60,62,67–73</sup>. A rabbit model of hypertension was used to study mild aortic valve stenosis<sup>74</sup>. In this study, echocardiography was used to assess the morphology and function of aortic valves, as well as left ventricular mass<sup>74</sup>. This study demonstrated that hypertensive rabbits tended to show reduced aortic valve area and increased valve thickness. Although the rabbit is often used to study VHD, the atherosclerotic lesions that are formed do not simulate those found in humans, limiting its suitability as a model of CVD<sup>66</sup>.

The pig can develop spontaneous lesions in the vasculature and cardiac valves, and has been widely used to study atherosclerosis<sup>75</sup>. The porcine cardiovascular system shares many similarities with that of humans, including heart anatomy and tri-layered aortic valve leaflets, as well as similar lipid profiles and lipoprotein metabolism<sup>76,77</sup>. These attributes highlight the pig as an ideal model for CAVD. Currently there are a number of research groups working to characterize cellular and molecular components in porcine valves. For example, aortic and ventricular side aortic VECs from adult male pigs have been compared, using microarray and qRT-PCR to measure gene expression<sup>78</sup>. In this study, side-specific expression differences were found between the aortic and ventricular VECs<sup>78</sup>. Interestingly, higher expression was noted in the aortic side of the valve of genes associated with vascular calcification and skeletal development, such as BMP-4<sup>78</sup>. Lower expression of factors shown to inhibit ectopic calcification was also observed in the aortic side VECs, including OPG, C-type natriuretic peptide (CNP) and chordin (an inhibitor of the osteoinductive activity of BMPs)<sup>78</sup>. This may permit aortic side-specific vulnerability to calcification. In addition to this, greater expression of antioxidative genes and an absence of differential expression of pro-inflammatory factors on the aortic side suggests potential protection in the normal valve against lesion development and inflammation<sup>23,78</sup>.

A porcine model of early aortic valve sclerosis has also been assessed<sup>61</sup>. In this investigation, pigs were fed either a standard or high fat/cholesterol (HF/HC) diet for 2–5 months. Swine fed on the HF/HC diet developed significantly thicker lesions on the aortic side of coronary aortic valve leaflets, with histologically opaque regions consisting of proteoglycans, collagen and elastin, within the fibrosa layer as similarly observed in early human CAVD<sup>61</sup>. Increased expression of osteochondrogenic markers including SRY (sex determining region Y)-box 9 (SOX9) and Msh Homeobox 2 (MSX2) has been observed in dense proteoglycan-rich lesion onlays with the HF/HC diet<sup>61</sup> as

Table 1. Examples of large animal models of calcific aortic valve disease (CAVD)

Animal model	Key findings	Reference
Pig	Aortic side valve endothelial cells (VECs) may be more susceptible to calcification.	Sider et al. 2014 <sup>61</sup>
	High fat/high cholesterol (HF/HC) diet induced thick proteoglycan lesions in the fibrosa layer (aortic side of valve) in an up to 5-month study.	Simmons et al. 2005 <sup>78</sup>
	HF/HC diet induced calcification in atherosclerotic lesions in an up to 48-week study.	Gerrity et al. 2001 <sup>77</sup>
Rabbit	Mild aortic valve stenosis in hypertensive rabbits, increased valve thickness and inflammation nodules, hypertrophy of valve after 4 months.	Cuniberti et al. 2006 <sup>74</sup>
	High cholesterol diet for 20 and 40 weeks, atherosclerotic lesions present in aortic valves, with increased lipid deposition, inflammatory cell infiltration, osteopontin (OPN) deposition, changes in collagen and elastin distribution, and mineralization.	Cimini et al. 2005 <sup>288</sup>
Dog	Canine aortic valve interstitial cells (VICs) spontaneously formed apparent calcified nodules containing hydroxyapatite within 2–3 weeks.	Mohler et al. 1999 <sup>62</sup>
Sheep	The inhibition of bone morphogenetic protein 2 (BMP-2) by Notch1 signalling in sheep aortic VICs is a potential mechanism by which aortic valve calcification is subdued.	Nigam and Srivastava 2009 <sup>289</sup>

have complicated atherosclerotic lesions with ectopic calcification<sup>77</sup>. Furthermore, there appears to be a higher susceptibility of the aortic side of the aortic valve leaflet to calcification and disease lesions<sup>79</sup>. Additional investigations are required to identify the side-specific components and mechanisms that may underlie these observations in the aortic side of the leaflets.

As inflammation plays a key role in the initiation and development of valve calcification, a gene profile of porcine aortic VICs (PAVICs) under elevated pressure was generated to study expression of inflammatory genes, with the results showing similarities to those seen in CAVD<sup>80</sup>. The ECM protein matrix metalloproteinase 3 (MMP3) and pro-inflammatory cytokine interleukin 6 (IL-6) were amongst those found to be upregulated in this study<sup>80</sup>. Furthermore, the inflammatory gene network revealed was associated

with the upregulation of tumour necrosis factor alpha (TNF $\alpha$ )<sup>80</sup>.

The similarities of early stages of aortic stenosis to atherosclerosis through the shared processes of lipid deposition, inflammation and calcification originally led to the idea that statins may be beneficial in CAVD patients. In clinical trials in patients, however, statin therapies surprisingly failed to produce reduction in the progression of aortic stenosis, despite significant decreases in serum LDL cholesterol levels<sup>81–83</sup>. While both lipid deposition and inflammation may be important processes in aortic stenosis, it may be likely that the accumulation and propagation of calcium crystals drives disease progression. Future therapies against aortic stenosis may involve lipid-lowering and calcification inhibiting effects, such as through a combination of statins and mineralization inhibitors.

### Vascular calcification and models

Vascular calcification is a disease of abnormal mineral metabolism, in which calcium phosphate crystals, in the form of hydroxyapatite (HA), are deposited in blood vessels<sup>84–86</sup>. It is a hallmark feature in ageing, hypertension and atherosclerosis<sup>86–88</sup>. For example, coronary artery calcification (CAC) predicts atherosclerotic burden in the arteries, which can be measured by computerized tomography (CT)<sup>4</sup>. The presence of CAC is an indicator of the presence of atherosclerotic plaque<sup>4</sup>. The pathological process of vascular calcification is a major, independent risk factor of cardiovascular mortality<sup>85</sup>.

Calcification can develop in the tunica media and/or the intima layers of blood vessels, resulting in the thickening and loss of elasticity of arterial walls<sup>86,89</sup>. Intimal calcification is typically found in large vessels and coronary arteries, and it involves intimal hyperplasia and atherosclerosis<sup>90</sup>. For medial calcification, dense calcium sheets form in the tunica media between VSMCs, which have been found to contain bone components, including bone trabeculae and osteocytes<sup>90</sup>. The latter form of calcification is most frequently exhibited in distal vessels of patients with advanced ageing, diabetes and kidney failure<sup>90</sup>.

Other than the blood vessels, calcification of the vascular system can also be found in the myocardium and the cardiac valves (as described previously), and ectopic calcification in these regions is associated with clinical symptoms<sup>84,91</sup>. Ectopic vascular calcification impairs blood flow and blood vessel compliance, making it an independent and strong predictor of death through cardiovascular risks, such as arterial hypertension, left ventricular hypertrophy and cardiomyopathy<sup>89,92,93</sup>.

Vascular calcification can be induced through the loss of mineralization inhibitors, as well as the initiation of ectopic bone formation<sup>94</sup>. This process shares many similarities with physiological bone mineralization, where there are proteins associated with bone formation being generated by VSMCs<sup>90,95,96</sup>. Extensive investigations in the last two decades have shown that pathological vascular calcification is a tightly regulated process, where vascular cells may acquire

osteoblast-like functions<sup>86</sup>. Vascular cell calcification can be stimulated by the same group of genes as those expressed during bone formation<sup>97</sup>. Atherosclerotic plaque calcification essentially involves the same biological processes as in normal bone formation<sup>98</sup>. Studies have characterized the mineral element of vascular calcification where the calcium deposits primarily exist in the form of HA, again, similar to that seen in bone<sup>99–102</sup>. In addition, the expression of numerous key mediators of bone formation and bone structural proteins are present, such as MGP, OPG and OPN<sup>101,103–106</sup>. Nonetheless, although the sequence of events leading to normal bone formation is well known, it is still unclear through which specific mechanisms vascular calcification occurs<sup>86,98</sup>. Calcification of atherosclerotic plaque has been attributed both beneficial and deleterious effects<sup>107</sup>. Mathematical models predict that microcalcifications of the thin fibrous cap of atherosclerotic plaque local stress concentrations that lead to interfacial debonding and plaque rupture<sup>108,109</sup>. And that the effect of microcalcification is increased with decreasing cap thickness<sup>110</sup>. In agreement with these predictions, histological examinations of ruptured human lesions found that rupture commonly occurs in areas of maximum circumferential stress<sup>111</sup>. Rupture in sites of lower stress suggests heterogeneity of plaque constituents, resulting in local stresses<sup>110,111</sup>. However, post mortem *in vitro* imaging of human atherosclerotic lesions found that microcalcification of the fibrous cap was rare<sup>108</sup>. Analysis of both stable and ruptured human lesions found that the lipid content of the lesions correlates with maximum circumferential stress and not with calcification<sup>112</sup>.

Increased calcium levels promote mineralization and influence various mechanisms in VSMCs that result in increased susceptibility to matrix mineralization<sup>84</sup>. Elevated calcium and phosphate induce VSMC calcification *in vitro*, causing VSMC phenotypic change<sup>85,113,114</sup>. In a calcified environment, VSMC populations contain cells that undergo phenotypic transitions to osteocytic, osteoblastic and chondrocytic cell types<sup>86,115</sup>. This phenotypic change is because of loss of VSMC markers and the gain of osteochondrogenic markers, including alkaline phosphatase (ALP), OPN and RUNX2<sup>86,116,117</sup>. Moreover, ectopic calcification may be a result of the loss of mineralization inhibitors. These include ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), ATP-binding cassette transporter subtype 6 (ABCC6), the CD73 ectonuclease and fibrillin 1 (FBN1)<sup>118</sup>.

It has yet to be discerned whether human vascular calcification causes, or is caused by, the expression of bone-related genes. Therefore, focus on the very early stages of ectopic calcification is critical. Explorations into this may be possible through the use of animal models, where disease progression and the underlying causes can be examined.

A number of popular rodent models exist. Non-uraemic models include transgenic mice that are deficient in known calcification inhibitors, such as Fetuin-A<sup>119</sup>, MGP<sup>120</sup> and OPG<sup>121</sup>. Vascular calcification can also be induced in rats by high doses of warfarin, which induces rapid calcification of vascular elastic lamellae and aortic valves<sup>122</sup>. These rats

are phenotypically similar to MGP knockout mice, suggesting similarity in underlying mechanisms<sup>122</sup>. Uraemic models of vascular calcification include the 5/6 nephrectomy rat. In this animal, renal failure is modelled by total nephrectomy of one kidney and the ligation of 2/3 of the extra-renal branches of the renal artery of the contralateral kidney<sup>123,124</sup>. These rats develop mild calcification predominantly in the aortic arch<sup>125</sup>. This calcification is exacerbated and accelerated by a high phosphate diet<sup>126</sup>, or 1,25 (OH)2 vitamin D3 treatment<sup>127–129</sup>. Uraemia can also be induced with excessive dietary adenine, of which a metabolite, 2,8 dihydroxyadenine, precipitates in the kidney inducing renal failure<sup>130</sup>. When fed a high phosphate diet following a high adenine diet, rats develop severe vascular calcification<sup>131</sup>. While several rodent models are presently employed in the field, a robust large animal model of vascular calcification has yet to be established. A brief summary of large animal vascular calcification models utilized to date can be found in Table 2.

A number of vascular calcification investigations have involved studies of the *ENPP1* gene. Loss-of-function mutations in the *ENPP1* gene, which encodes ENPP1, also known as plasma cell membrane glycoprotein 1 (PC-1), have been associated with rare human genetic disorders<sup>132–135</sup>. Mutations of this gene are linked with a genetic deficiency in pyrophosphate levels causing a life-threatening disorder known as Generalized Arterial Calcification of Infancy (GACI), a rare autosomal recessive disease characterized by arterial calcification, fibrosis and stenosis, which leads to premature death in neonates<sup>84,93,132,134,136,137</sup>. As a recessive disorder, the most severe mutations are those that associate with the loss of enzymatic function<sup>93</sup>. The significance of *ENPP1* mutations is seen in infants with GACI, who often die with extensive vascular calcification afflicting nearly all arterial beds, including the coronary arteries<sup>93</sup>.

The genetically engineered *Enpp1* null mouse model has been used extensively to investigate medial aortic calcification. However, the degree of calcification in this model is significantly milder than in affected patients. Therefore, there is a clear need for a more physiologically comparable large animal model to allow for the development of targeted therapeutic treatments for this devastating rare disease.

Reports of calcification in large arteries of racehorses have been made, including the aorta, pulmonary artery and carotid arteries<sup>138–140</sup>. Arroyo *et al.* (2008) investigated the prevalence, distribution and severity of vascular calcification in both young adult Thoroughbred and Standardbred racehorses. This study showed material consistent with HA, found in vascular calcification, to be present in calcified lesions. Microscopic evaluation revealed thinned, fragmented and calcified elastic fibres in the tunica media of the pulmonary arteries, which were encompassed by dense collagen matrix<sup>141</sup>. Furthermore, both breeds and sexes appeared to be similarly affected<sup>141</sup>. Studies using these horses may be useful for human calcification research, although it is important to note that calcification can be found in relatively early ages in horses (below 5 years of age), especially in those with a racing background<sup>139</sup>. What contribution



Table 2. Examples of large animal models of vascular calcification

Animal model	Key findings	Reference
<i>Pig</i>	Substantial expression of ectonucleoside triphosphate diphosphohydrolase 1 (eNTPD1, CD39) and ecto-5'-nucleotidase (e5NT, CD73) in aortic valve interstitial cells (VICs) and valve endothelial cells (VECs)—may be important in valves. Both factors influence extracellular nucleotide concentrations, thus may be important in valve pathology.	Kaniewska et al. 2014 <sup>19</sup>
<i>Horse</i>	Sporadic calcification of large arteries (in the tunica media) in racehorses mainly observed in the pulmonary artery (also in aortic, pulmonary and carotid trunks). Observed disorganized collagen and elastin fibres, and presence of chondrocyte/osteoblast-like cells. Analysis revealed the mineral found was consistent with hydroxyapatite.	Arroyo et al. 2008 <sup>141</sup>
<i>Cow</i>	Bovine aortic smooth muscle cell (BASC) calcification induced with $\beta$ -glycerophosphate. Results found mineral deposition in basal matrix of multilayered areas, presence of extracellular matrix vesicles, calcifying collagen fibrils and calcified nodules. Osteopontin (OPN) inhibited calcification dose-dependently, but did not inhibit alkaline phosphatase activity or decrease phosphorus levels in culture medium. BASMC calcification induced with $\beta$ -glycerophosphate or inorganic phosphate. Found increased mRNA expression of decorin (protein expressed in skeletal tissues), and overexpression and supplementation of exogenous decorin with calcification medium increased BASMC mineralization. BASMC calcification induced with inorganic phosphate. Tropoelastin potentially inhibits calcium deposition in the cultured BASMCs through interactions with elastin binding protein (EBP).	Wada et al. 1999 <sup>290</sup>  Fischer et al. 2004 <sup>291</sup>  Wachi et al. 2004 <sup>292</sup>

training and athleticism contribute to these changes is not known, but horses do develop heart valve changes as they progress through training programmes. Ectopic calcification occurring without experimental induction may make the horse a useful model of disease progression, as well as tissue being available from those horses that are euthanized.

At present, there are a limited number of medical approaches with the potential to treat or prevent the progression of vascular calcification and other associated conditions, such as aortic stenosis. An example is the use of the bisphosphonate etidronate, which is currently used for the treatment of GACI<sup>142</sup>. Bisphosphonates are strong inhibitors of osteoclast activity, and are widely used in clinical practice to prevent bone loss associated with conditions such as osteoporosis, Paget's disease and metastatic bone disease<sup>143</sup>. The prolonged use of etidronate can have undesirable effects, such as severe skeletal toxicity as reported in a 7-year-old GACI patient<sup>144</sup>. Because of this, the use of etidronate requires close monitoring when administered.

A more recent study describes a potential treatment for vascular calcification using enzyme replacement therapy<sup>145</sup>. Daily subcutaneous administration of ENPP1-Fc, a soluble, recombinant protein with the extracellular domain of ENPP1 fused to the fragment crystallisable (Fc) region of human immunoglobulin G1 (IgG1), was effective against GACI in a mouse model<sup>145</sup>. This very promising preclinical study may be the first step to clinical trials with enzyme replacement therapy in GACI patients.

#### *Aortic dysfunction and FBN1 in Marfan syndrome*

Diseases of the aortic root and ascending aorta are frequent causes of aortic regurgitation. Aortic regurgitation can be a consequence of abnormal aortic leaflets, as well as structural defects in the aortic root and annulus<sup>18</sup>. Various congenital faults can lead to aortic regurgitation, for example Marfan syndrome (MFS, OMIM 154700), which is an autosomal dominant connective tissue disorder<sup>18,27</sup>. Mutations of the *FBN1* gene are linked with aortic aneurysms and elastic fibre calcification observed in patients with MFS<sup>26,27,146</sup>. The fibrillin proteins, predominantly FBN1, are the major structural components of the 10-nm microfibrils of the ECM<sup>147,148</sup>. They are also involved in regulating the bioavailability of TGF- $\beta$ . FBN1 is a 350-kDa glycoprotein, which polymerizes and aggregates to form flexible extracellular microfibrillar structures<sup>27</sup>.

Patients with MFS show a broad range of cardiovascular defects. These include thoracic aortic aneurysms that result in aortic dissection, rupture or both<sup>149</sup>. Dilatation of the root of the aorta leads to failure of aortic valve occlusion resulting in valve insufficiency. Additionally, MFS can involve dysfunction of the mitral valve (myxomatous thickening, prolapse and regurgitation), and medial degeneration morphologically similar to that observed during ageing, in idiopathic aortic aneurysms, and in sufferers of aortic valve disease and hypertension<sup>27</sup>. Prophylactic treatment with beta blockers and angiotensin II receptor antagonists (for example losartan) has proved effective in reducing the rate of

aortic dilatation and hence aortic valve dysfunction<sup>150</sup>, although there are no treatments for the underlying defect in the *FBN1* protein.

Cattle have been established as a model of human MFS. There are a number of spontaneous *FBN1* mutations in cattle, resulting in a condition that shares many of the clinical and pathological manifestations of human MFS<sup>151–153</sup>. Diminished expression of fibrillin has been found in cultured bovine MFS dermal fibroblasts and BASMCs, similar to the findings in human MFS, and pulse-chase metabolic labelling experiments verified decreased incorporation of fibrillin into the ECM<sup>154</sup>. Mutations in *FBN1* have also been detected in cattle afflicted with MFS, with similar clinical features as observed in human MFS<sup>153,155</sup>.

The *FBN1* protein is suggested to be a potential inhibitor of vascular calcification, because mice with a knock-out of *FBN1* displayed ectopic calcification<sup>156,157</sup>. A large animal *in vitro* study with cultured bovine aortic smooth muscle cells found that with accelerated calcification the expression of *FBN1* was reduced<sup>158</sup>. These findings may suggest pathological interactions between MFS and vascular calcification, adding to the complexity of the calcification process.

A related condition is bicuspid aortic valve (BAV) which is the most common congenital valve abnormality, with an incidence of around 1%<sup>159</sup>. This condition is responsible for nearly 50% of surgeries for isolated severe aortic stenosis<sup>160</sup>. Although the phenotype is extremely variable, BAV can be familial, with some cases resulting from mutations in *NOTCH1*<sup>38,161,162</sup>. The bicuspid valve undergoes age-associated calcification similar to the tricuspid valve, but at a younger age, so that most BAVs have significant calcification by the time the individual reaches 40 years of age<sup>163</sup>. In mouse models, BAV has been associated with *Nos3*, *Gata4*, *Gata5*, *Gata6* and *Nkx2.5* mutations<sup>160,164</sup>. Patients with BAV are also at risk of thoracic aneurysms, and abnormalities of *FBN1* protein have been demonstrated in the VSMCs of BAV aorta<sup>165</sup>.

## ATHEROSCLEROSIS

Atherosclerosis is a chronic inflammatory disease, and affects medium to large sized arteries<sup>166,167</sup>. It is a major CVD, which can lead to stroke, myocardial infarctions and peripheral vascular disease in humans<sup>166</sup>. Various animal models have been developed and have greatly contributed to the understanding of this disease. Large animal models of atherosclerosis have been generated, including the rabbit, pig, goat and non-human primates<sup>166,168</sup>.

Initially, atherosclerotic lesions consist of non-protruding fatty streaks composed of lipid loaded macrophages known as foam cells. As the lesion progresses, VSMCs switch to a proliferative synthetic phenotype, which produces excessive amounts of collagen. As macrophages, foam cells and VSMCs accumulate, the lesion intrudes into the lumen causing disturbed flow. This disturbed flow exacerbates endothelial dysfunction, further provoking the lesion. The increased involvement of VSMCs, along with extracellular accumulation of oxidized LDL and necrotic cell debris, results in

structural weakening. Vulnerable lesion rupture results in thrombosis of the vessel and ischemia of the downstream tissue<sup>169,170</sup>.

Atherosclerosis shows a tendency to develop in areas of disturbed or low shear stress, such as bifurcations and curvatures. Indeed, turbulent flow causes endothelial dysfunction *in vitro*<sup>171</sup>. Hyperlipidaemia is also an important factor in the development of atherosclerosis. The causal relationship between LDL and atherosclerosis has been extensively studied<sup>169,170,172–175</sup>.

The ideal model of atherosclerosis would develop lesions that progress through all stages of the disease, from fatty streak development to unstable plaque rupture. Murine models offer several advantages in general as stated above. For the study of atherosclerosis, the most commonly cited advantages are the short time frame of plaque development, and the comparative ease of genetic manipulation. Wild type mice, however, rarely develop atherosclerosis. Unlike humans, the major circulating lipoprotein in mice is HDL, rather than LDL, which is the key player in atherosclerosis progression in humans. Additionally, mice lack cholesteryl ester transfer protein (CETP)<sup>176</sup>, exacerbating the resistance of these animals to atherosclerosis. CEPT facilitates the exchange of cholesterol and triglycerides between HDL and Apo lipoprotein B, simultaneously decreasing HDL while increasing LDL<sup>177</sup>. Clinically, low CETP activity is associated with decreased CVD risk<sup>177</sup>. Overcoming the atheroresistant phenotype of mice requires genetic manipulation of their lipoprotein metabolism to produce a more proatherogenic phenotype. The two most commonly used models are the Apo lipoprotein E deficient (ApoE<sup>-/-</sup>) mice and the LDL receptor deficient (LDLR<sup>-/-</sup>) mice.

ApoE is produced by the liver and macrophages and is incorporated into circulating lipoproteins. Through binding of LDLR and LDLR related protein ApoE mediates the clearance of LDL and very low density lipoprotein (VLDL) from the circulation<sup>178</sup>. Complete deficiency of ApoE in humans is rare. However, the ApoE2 isoform binds LDLR poorly and has a high prevalence in patients with congenital type III hyperlipoproteinemia<sup>179–181</sup>. The genetic ablation of ApoE in mice results in significantly increased circulating VLDL<sup>182,183</sup>. These mice reliably and rapidly develop atherosclerotic lesions; as a result, they have been widely employed in the study of atherosclerosis<sup>182,183</sup>. Despite their usefulness and reliability, the predominant circulating lipoprotein in these mice is VLDL, not LDL, which like wild type mice is markedly different to humans. These animals are also dramatically hyperlipidaemic when fed a chow diet<sup>183</sup>. This hyperlipidaemia is greatly exacerbated when fed a high fat diet<sup>183</sup>. ApoE has also been demonstrated to possess immuno-regulatory, anti-inflammatory and antioxidant properties<sup>184–187</sup>. In light of the role that low chronic inflammation plays in the progression of atherosclerosis, the rapid lesion progression, extreme hyperlipidaemia and pro-inflammatory state may be considered limitations rather advantages of this murine model.

LDLR<sup>-/-</sup> mice are more moderate models of atherosclerosis compared to ApoE<sup>-/-</sup> mice. These mice gradually develop

atherosclerotic lesions on a chow diet, which can be accelerated by high fat feeding<sup>166,183</sup>. In a closer approximation to the human disease, the predominant lipoprotein in these mice is LDL<sup>166,183</sup>. LDLR deficiency in humans is the most common cause of familial hypercholesterolemia<sup>188,189</sup>. The LDLR<sup>-/-</sup> model has been further manipulated to generate mice that express only apoB100<sup>190</sup> or transgenic human apoB100<sup>191</sup>. In both cases, these mice develop accelerated atherosclerosis on a standard chow diet<sup>190,191</sup>.

In mice, atherosclerotic plaques predominantly develop in the aortic sinus, aortic arch and brachiocephalic artery, in contrast to human plaque, which primarily develops in the carotid arteries, the coronary arteries and the aortic arch<sup>16,166</sup>. Although significant insight into the initiating mechanisms has been gained from mouse studies, it is noteworthy that the progression, response to treatment and regression of atherosclerotic plaque vary significantly between vascular beds<sup>192,193</sup>. Another important limitation of mouse models is the rarity of advanced coronary lesions that progress to rupture and thrombosis<sup>166,194</sup>. This is a common complication of atherosclerosis in humans that cannot be modelled in these animals.

One ethical and practical concern when designing experiments involving high fat fed mice or ApoE<sup>-/-</sup> mice is their tendency to develop eruptive skin lesions and ulcerative dermatitis<sup>195,196</sup>. This is a source of significant pain and inflammation, and often requires premature humane euthanasia<sup>195,196</sup>.

Spontaneous atherosclerosis can occur in swine and ruminant species<sup>197–200</sup>. Experimental induction of this disease has been performed in calves and goats, with reported characteristics similar to human atherosclerosis<sup>168,201,202</sup>. In a study by Hines *et al.* (1985), young male goats were used to assess the effects of dietary calcium and cholecalciferol on plasma and tissue cholesterol concentrations, the distribution of total lipid in the body, and aortic and plasma concentrations of calcium and magnesium<sup>168</sup>. Outcomes of this study found that this diet may not affect cholesterol and/or total lipid metabolism. However, effects on deposition of lipid and mineral in arterial walls were noted, and aortic calcification, as well as lipid infiltration and plaque formation, may predispose an individual to atherosclerosis<sup>168</sup>. Whilst the goat model may be of limited use because of the relatively short amount of time for atherosclerosis to develop compared to humans, further studies with the goat may contribute to increased understanding of the mechanisms underpinning CVDs.

Pigs have also been used as a model for atherosclerosis<sup>203–205</sup>. Atherosclerosis develops slower in pigs compared to mice. Pigs also develop lesions spontaneously, and in time, these lesions develop in the coronary vasculature<sup>75,206,207</sup>. Atherosclerosis can be induced in pigs through an atherogenic diet<sup>75,206,207</sup>. HF/HC fed pigs develop complex atherosclerotic lesions that share many of the pathological features of human lesions, including smooth muscle cells, inflammatory infiltrates, foam cells, fibrous caps, necrotic and apoptotic cells, plaque haemorrhage, calcification and expanded extracellular matrices<sup>208–211</sup>. Anatomically,

the distribution of lesions in the pig is similar to humans, and more importantly, these include a propensity for lesions to develop in the coronary circulation<sup>16,208–212</sup>. One proposed reason for these similarities between man and pig is the similarity of lipoprotein profile between the two species<sup>16,166</sup>. A recent study using young adult male pigs fed on a high fat diet for 20–24 weeks assessed the effects of hypercholesterolaemia, with the aim to examine early stage atherosclerosis<sup>204</sup>. Significantly greater intima-media thickness of the abdominal aorta, carotid artery and femoral artery, indicated relatively rapid progression of vessel disease<sup>204</sup>. This is consistent with past reports in humans demonstrating that increased thickness of the walls of the abdominal aorta and carotid artery can independently predict atherosclerosis, coronary artery disease, myocardial infarction and stroke<sup>213–216</sup>. Associations of CVD risk factors and events have also been associated with increased intima-media thickness of the femoral artery<sup>217</sup>.

Spontaneous familial hypercholesterolemia has also been reported in pigs<sup>218,219</sup>. These pigs have the arg94 residue of their LDLR substituted by a Cys resulting in a missense mutation<sup>220,221</sup>. These pigs have excessive circulating LDL and reduced HDL, and as a result, they develop severe atherosclerosis in the coronary and aortic arteries, even while fed a standard pig diet<sup>218,219</sup>. Transgenic familial hypercholesterolaemia miniature pigs have also been produced in order to evaluate atherosclerosis<sup>222,223</sup>. These minipigs recapitulate several of the features observed in human atherosclerosis<sup>223</sup>. An important translational feature of pig models is the possibility of percutaneous coronary intervention using human clinical equipment and stents<sup>224–229</sup>. Furthermore, pig models also develop restenosis<sup>226,230</sup>, a common complication of stent implantation that compromises long-term outcomes<sup>226</sup>. On the whole, the porcine model has great potential in uncovering the more specific details in atherosclerotic progression. The minipig is also advantageous, as it requires lower maintenance costs compared to larger animals.

## DIABETES MELLITUS ACCELERATED ATHEROSCLEROSIS

Cardiovascular complications are common in diabetes mellitus (DM) patients and include cardiomyopathies and accelerated atherosclerosis. DM patients are usually grouped into two different types based primarily on aetiology. Type 1 DM (T1DM) is characterized by hyperglycaemia because of a deficiency in insulin that is the result of autoimmune destruction of  $\beta$ -cells in the pancreas. Type 2 DM (T2DM), on the other hand, is characterized by hyperglycaemia because of insulin resistance. T2DM is typically preceded by a hyperinsulinaemic euglycemic period. Glucotoxicity and lipotoxicity in T2DM lead to progressive destruction of  $\beta$ -cells, and ultimately hypoinsulinaemia. Commonly, T2DM patients are also obese with some degree of dyslipidaemia. T2DM accounts for 95% of DM patients and is more commonly associated with CVD than T1DM<sup>169,170</sup>.



Researchers have employed several approaches to develop animal models of DM. These approaches are dependent on the type of DM to be modelled. For T1DM, a common approach is ablation of  $\beta$ -cells with pharmacological agents, such as Alloxan and Streptozotocin (SZT), where these chemicals are taken up by  $\beta$ -cells and induce free radical formation leading to cytotoxicity<sup>231–234</sup>. SZT treatment in wild type mice has been shown to induce hyperglycaemia, but with a modest reduction in insulin production<sup>235</sup>. When fed a high fat diet, these mice show increased size of fatty streaks<sup>235,236</sup>. SZT treatment in ApoE mice results in hyperglycaemia and insulin deficiency<sup>237,238</sup>. Hypercholesterolaemia in these mice is exacerbated by SZT. This increased cholesterol is primarily VLDL and LDL. Of particular importance is the dramatic increase in atherosclerotic lesion area in the SZT mice compared to non-treated controls<sup>237,239,240</sup>. The increase in atherosclerosis in these animals has been attributed to hyperglycaemia and the formation of advanced glycation end products<sup>237</sup>. Interestingly, SZT-treated LDLR mice display no differences in atherosclerosis development compared to untreated LDLR mice<sup>241</sup>. Pigs have also been employed in studying the effects of DM on atherosclerosis. Yucatan miniature pigs fed a high fat diet and treated with Alloxan develop hypercholesterolaemia and insulin resistance<sup>242</sup>. When compared to high fat fed untreated pigs, the high fat fed Alloxan-treated group showed significantly increased coronary atherosclerosis<sup>243</sup>. Similarly, Alloxan treatment in conjunction with high fat feeding increased atherosclerosis in Sinclair miniature pigs<sup>76</sup>.

The models described above have provided important insights into the effects of hyperglycaemia on atherosclerosis. These models do however require some degree of  $\beta$ -cell reduction. This, depending on the degree of reduction, resembles T1DM more than T2DM. A common method to induce T2DM in animals is a dietary approach. For example, high fat, but not high fructose, fed ApoE<sup>-/-</sup> mice develop fasting hyperglycaemia and hypoinsulinaemia consistent with T2DM<sup>244</sup>. These mice have significantly increased atherosclerosis compared to control diet ApoE<sup>-/-</sup> mice<sup>244</sup>. Similarly, high fat, but not high fructose diet, induces diabetes and increases atherosclerosis in LDLR<sup>-/-</sup> mice<sup>245</sup>.

Mice with impaired leptin signalling lack a sense of satiety, and as a result are characterized by excessive feeding and obesity. These mice readily develop insulin resistance. Similar to high fat fed wild type mice, they do not reliably develop atherosclerosis because of the majority of their circulating cholesterol being HDL. To investigate the effects of DM on atherosclerosis, LDLR<sup>-/-</sup> mice have been crossed with either leptin deficient mice (Lep<sup>ob/ob</sup>) or leptin receptor deficient mice (lepr<sup>db/db</sup>). These mice are obese with hypercholesterolaemia because of both elevated LDL and VLDL<sup>246,247</sup>. These mice also have extensive spontaneous atherosclerotic lesions<sup>247–251</sup>. The primary difference between the two strains is ApoE<sup>-/-</sup> lepr<sup>db/db</sup> have high circulating leptin levels<sup>252</sup>. Similarly, double knock out ApoE<sup>-/-</sup> Lep<sup>ob/ob</sup> and ApoE<sup>-/-</sup> lepr<sup>db/db</sup> are also obese with hypercholesterolaemia and insulin resistance<sup>252–254</sup>.

Atherosclerosis is accelerated and exacerbated compared to ApoE<sup>-/-</sup> only mice<sup>252–255</sup>. Hypercholesterolaemia in these mice is extreme, and concerns have been raised over the interpretation of results from these animals<sup>256</sup>.

Ossabow pigs have a natural propensity for obesity<sup>257</sup>. When fed a high fat diet, these pigs develop obesity with decreased glucose tolerance and hyperinsulinaemia<sup>258–260</sup>. High fat feeding also induces hypercholesterolaemia with a predominant increase in LDL cholesterol<sup>259–261</sup>. Neointimal hyperplasia and atherosclerosis are significantly increased in the coronary circulation on these pigs<sup>258,261</sup>. Compared to Yucatan pigs, Ossabow pigs recapitulate more closely the metabolic and cardiovascular phenotype of DM and atherosclerosis<sup>258</sup>.

### ABDOMINAL AORTIC ANEURYSM (AAA)

Abdominal aortic aneurysm (AAA) is the tenth leading cause of death in men above 60, with 6–9% of males over 65 year old being affected, and is becoming more common in women<sup>262</sup>. Clinical risk factors for AAA include ageing, gender, hypertension, smoking and a family history of aneurysm disease<sup>262–265</sup>. However, the risk of smaller aneurysm rupture in women is greater than in men<sup>264</sup>. AAA involves inflammatory cell infiltration, SMC apoptosis in the aortic wall and ECM degradation<sup>266</sup>.

As with many CVDs, the lack of samples from healthy or early stage disease patients hinders research. Accordingly, Riches *et al.* (2013) examined the biology of SMCs from isolated porcine carotid arteries to assess the potential of this model for AAA<sup>263</sup>. Porcine arterial SMC samples exposed to combined collagenase/elastase treatment in a bioreactor share phenotypic features with cultured end-stage AAA human SMC samples<sup>263</sup>. The study of SMCs from a large animal source and the use of a bioreactor to maintain an *ex vivo* model would be of value in studies of blood vessel wall components in vascular disease.

### CORONARY HEART DISEASE

Coronary heart disease (CHD) is the single most common cause of cardiovascular-related deaths in Europe and the USA, accounting for almost 380 000 deaths in 2010 in the USA, and around 74 000 deaths in the UK<sup>4,267,268</sup>. Various large animal models have been generated through the induction of coronary artery narrowing or occlusion. In a pig model of atherosclerotic CHD the site and time point of coronary occlusions were unpredictable and thus this model is inappropriate for research into CHD-related heart failure, where it is important to characterize the precise progression of the disease<sup>267</sup>. The response to injury in the coronary arteries of pigs is comparable to that in the human<sup>269,270</sup>. As the biological processes seen in arterial repair are similar between the pig and human, these pre-clinical studies are extremely valuable<sup>6</sup>. Other models of heart failure involve surgically constricting the coronary arteries or artificially producing intracoronary embolisms. This approach has been used in dogs and pigs (reviewed in<sup>267</sup>).



## FUTURE DIRECTIONS: POTENTIALS OF LARGE ANIMAL TRANSGENIC MODELS

There is still much progress to be made in the field of CVDs, and the generation of more suitable large animal models, such as the pig, would be highly valuable in examining the underlying processes that lead to the initiation and progression of this disease. As will be briefly commented on below, the use of novel genetic engineering techniques may play a role in furthering our understanding of CVDs.

## USE OF TRANSGENIC TOOLS

Substantial progress has been made in the fields of genetic manipulation and molecular cloning. These tools create a large window of opportunities for creating refined models for future biomedical research. Such models will facilitate studying the pathophysiology of human diseases, and be instrumental in improving and developing new diagnostic tests and therapeutic approaches.

Transgenic model systems have been established using organisms like the fruit fly (*Drosophila melanogaster*), rodents and zebrafish<sup>271</sup>. Although these models are highly informative, they do not sufficiently emulate the complexities of human biology. Consequently, the models of human disease often do not adequately mimic the human condition.

There is now increased potential for genetically engineered large animal models of human disease. In particular, the pig is becoming an increasingly relevant model organism for this approach to developing models. This is largely because of closer similarities with humans in terms of anatomy, genetics and physiology than the classical animal models. Pigs are relatively easy to breed, produce large litters, are available in a range of genotypes and phenotypes and provide access for biopsies and post-mortem samples<sup>271</sup>. As mentioned previously, miniature pigs have already proven to be valuable in biomedical research, including the field of cardiovascular biology<sup>222,223,272</sup>.

A major goal in biological research is to further our understanding on the relationships between genotype and phenotype. Traditional approaches in understanding gene function have been restricted because of the lack of required tools for gene customization<sup>273</sup>. More recently the possibilities of gene customization have expanded rapidly through the development of new and innovative technologies in the field of genome engineering, such as the use of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPRs). These next generation technologies serve as powerful tools for gene knock-out and targeted manipulation of genomes (Figure 4).




Figure 4. TALEN or CRISPR/Cas9 systems of gene editing. After zygote injection of customized transcription activator-like effector nuclease (TALEN) mRNA or Cas9 mRNA/single guide RNA (sgRNA), the gene of interest can be targeted and cut to produce a double strand break (DSB). TALENs work in pairs as the FokI endonuclease requires dimerization in order to produce a DSB. Various CRISPR/Cas9 systems exist for different applications. Fundamentally, the sgRNA directs the Cas9 nuclease to the site of targeting. After a DSB is created, DNA repair mechanisms occur via two main pathways: non-homologous end joining (NHEJ) and homology directed repair (HDR). NHEJ leads to insertion/deletion mutations (indels), whilst HDR can be used to insert desired sequences. Through these mechanisms, an edited animal can be produced

The first widely used genome editor was the ZFN<sup>274</sup> and along with TALEN technology has been effective in genome editing of cultured cells and numerous species leading to the production of transgenic rats, zebrafish, and pigs<sup>275–278</sup>. More recent to the TALEN editing platform, the CRISPR and Cas9 (the latter of which is a class of RNA-guided endonuclease) system is rapidly evolving as a novel genome editing technology<sup>279</sup>. This is due its ability to achieve precise genome editing to induce the specific mutations that have been observed in human patients, in a manner that leaves no molecular footprint within the target genome.

The CRISPR/Cas9 technology has also been used in large animals. Gene knockout in goats has achieved an efficiency of 9–70% of induced mutations in primary fibroblasts, with success in generating cloned goats with bi-allelic mutations, although cloning efficiency was low (1.1%), similar to other groups<sup>280,281</sup>. CRISPR/Cas9 has also been used in pigs, where the von Willebrand factor (*vWF*) gene, whose deficiency causes severe von Willebrand disease in humans, was targeted<sup>282</sup>. In this study, 68% piglets born through zygote injection had edited genomes, with 55% of these bearing bi-allelic mutations and 45% with mono-allelic mutations<sup>282</sup>. The overall high birth and survival rates indicate little toxicity from injecting with Cas9 mRNA and single guide RNA (sgRNA)<sup>282</sup>. These studies demonstrate that this transgenic tool can be used in livestock species, and can contribute to numerous applications of large animals in biomedical research.

There are limitations to the use of transgenic models, because of the present lack of information on the molecular biology of large mammalian organisms. Recent efforts have been dedicated to characterising these animals at the molecular level, for example in terms of their genomics, transcriptomics and proteomics. The pig genome has been extensively sequenced<sup>283</sup> as has the sheep genome<sup>284</sup>. Information is also available for the genomes of dog, cat, bovine, horse, guinea pig and rabbit (see <http://www.ensembl.org>), all of which can provide natural or transgenic models for human CVD. Although the gene annotation and assembly of the porcine genome are incomplete, genomic comparisons between the pig and human do demonstrate more structural resemblance than between mice and human<sup>285,286</sup>. Transcriptomic analysis of pig RNA also shows greater similarity with human than does mouse<sup>287</sup>. With the combination of innovative and efficient transgenic tools coupled with biologically relevant models of human diseases, there is little doubt that major advances in the cardiovascular field will be made in the areas of drug discovery, and targeted therapies for CVDs.

## CONCLUSIONS

Large animal models of human disease are valuable resources for identifying and gaining knowledge on the underlying factors in the progression of CVDs and the

mechanisms of action. Understanding the critical molecular processes and the role of fundamental drivers that lead to CVDs is important in ensuring successful outcomes of interventional and therapeutic approaches. With the advancements of state-of-the-art genome editing technologies like TALENs and CRISPRs, customisable models can be developed, which will greatly enhance the field of cardiovascular research. This can allow for more translational research potentially leading to treatments for human cardiovascular disorders, both congenital and acquired.

## ACKNOWLEDGEMENTS

This study was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) in the form of an Institute Strategic Programme Grant BB/J004316/1 (VEM, KMS, and CBAW), an Institute Career Path Fellowship BB/F023928/1 (VEM) and studentship funding via the East of Scotland BioScience Doctoral Training Partnership BB/J01446X/1 (EASTBIO DTP) (HGT).

## CONFLICT OF INTEREST

The authors have declared that there is no conflict of interest.

## REFERENCES

1. Solomon EP, Berg LR, Martin DW. *Biology*. Thomson-Brooks/Cole, London: Belmont, Calif., 2008.
2. Ross MH, Pawlina W. *Histology: A Text and Atlas: With Correlated Cell and Molecular Biology*. Lippincott Williams & Wilkins: Philadelphia, Pa.; London, 2011.
3. Lozano R, Naghavi M, Foreman K, *et al.* Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**: 2095–2128. doi:10.1016/S0140-6736(12)61728-0.
4. Go AS, Mozaffarian D, Roger VL, *et al.* Executive summary: heart disease and stroke statistics—2014 update a report from the American Heart Association. *Circulation* 2014; **129**: 399–410. doi:10.1161/01.cir.0000442015.53336.12.
5. WHO. *World Health Statistics 2014*. World Health Organization: Geneva, 2014.
6. Suzuki Y, Yeung AC, Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. *JACC Cardiovasc Interv* 2009; **2**: 373–383. doi:10.1016/j.jcin.2009.03.004.
7. Walters EM, Wolf E, Whyte JJ, *et al.* Completion of the swine genome will simplify the production of swine as a large animal biomedical model. *BMC Med Genomics* 2012; **5**: 55. doi:10.1186/1755-8794-5-55.
8. Chorro FJ, Such-Belenguer L, López-Merino V. Animal models of cardiovascular disease. *Rev Esp Cardiol* 2009; **62**: 69–84.
9. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. *Circ Heart Fail* 2009; **2**: 262–271. doi:10.1161/CIRCHEARTFAILURE.108.814459.
10. Munford RS. Murine responses to endotoxin: another dirty little secret? *J Infect Dis* 2010; **201**: 175–177. doi:10.1086/649558.
11. Warren HS, Fitting C, Hoff E, *et al.* Resilience to bacterial infection: difference between species could be due to proteins in serum. *J Infect Dis* 2010; **201**: 223–232. doi:10.1086/649557.

12. Doeing DC, Borowicz JL, Crockett ET. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. *BMC Clin Pathol* 2003; **3**: 3. doi:10.1186/1472-6890-3-3.
13. Meurens F, Summerfield A, Nauwynck H, et al. The pig: a model for human infectious diseases. *Trends Microbiol* 2012; **20**: 50–57. doi:10.1016/j.tim.2011.11.002.
14. Dumonde DC, Pulley MS, Paradinas FJ, et al. Histological features of skin reactions to human lymphoid cell line lymphokine in patients with advanced cancer. *J Pathol* 1982; **138**: 289–308. doi:10.1002/path.1711380402.
15. Crowle AJ. 1975. Delayed hypersensitivity in the mouse. In *Advances in Immunology*, Dixon FJ, Henry GK (eds.). Academic Press: London, 197–264.
16. Vilahur G, Padro T, Badimon L. Atherosclerosis and thrombosis: insights from large animal models. *BioMed Res Intern* 2011; **2011**.
17. Lunney JK. Advances in swine biomedical model genomics. *Int J Biol Sci* 2007; **3**: 179–184.
18. Maganti K, Rigolin VH, Sarano ME, et al. Valvular heart disease: diagnosis and management. *Mayo Clin Proc* 2010; **85**: 483–500. doi:10.4065/mcp.2009.0706.
19. Kaniewska E, Sielicka A, Sarathchandra P, et al. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (cd39) and ecto-5'-nucleotidase (cd73) in pig aortic valves. *Nucleosides Nucleotides Nucleic Acids* 2014; **33**: 305–312. doi:10.1080/15257770.2014.885985.
20. Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. *Circulation* 2008; **118**: 1864–1880. doi:10.1161/CIRCULATIONAHA.108.805911.
21. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease—2011 update. *Circulation* 2011; **124**: 1783–1791. doi:10.1161/CIRCULATIONAHA.110.006767.
22. Leopold JA. Cellular mechanisms of aortic valve calcification. *Circ Cardiovasc Interv* 2012; **5**: 605–614. doi:10.1161/CIRCINTERVENTIONS.112.971028.
23. Butcher JT, Mahler GJ, Hockaday LA. Aortic valve disease and treatment: the need for naturally engineered solutions. *Adv Drug Deliv Rev* 2011; **63**: 242–268. doi:10.1016/j.addr.2011.01.008.
24. Balaoing LR, Post AD, Liu H, et al. Age-related changes in aortic valve hemostatic protein regulation. *Arterioscler Thromb Vasc Biol* 2014; **34**: 72–80. doi:10.1161/atvbaha.113.301936.
25. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signaling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. *J Endocrinol* 2011; **209**: 139–151. doi:10.1530/JOE-10-0377.
26. Davis MR, Summers KM. Structure and function of the mammalian fibrillin gene family: implications for human connective tissue diseases. *Mol Genet Metab* 2012; **107**: 635–647. doi:10.1016/j.ymgme.2012.07.023.
27. Ramirez F, Pereira L. Mutations of extracellular matrix components in vascular disease. *Ann Thorac Surg* 1999; **67**: 1857–1858; discussion 1868–1870. DOI: S0003497599004373 [pii]
28. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. *Circulation* 2005; **111**: 3316–3326. doi:10.1161/CIRCULATIONAHA.104.486738.
29. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. *Eur Heart J* 2003; **24**: 1231–1243.
30. Cowell SJ, Newby DE, Boon NA, et al. Calcific aortic stenosis: same old story? *Age Ageing* 2004; **33**: 538–544. doi:10.1093/ageing/afh175.
31. Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med* 1999; **341**: 142–147. doi:10.1056/NEJM199907153410302.
32. Ortlepp JR, Schmitz F, Bozoglu T, et al. Cardiovascular risk factors in patients with aortic stenosis predict prevalence of coronary artery disease but not of aortic stenosis: an angiographic pair matched case–control study. *Heart* 2003; **89**: 1019–1022.
33. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. *Circulation* 1994; **90**: 844–853.
34. Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). *Am J Cardiol* 1995; **76**: 928–932.
35. Bach DS, Siao D, Girard SE, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. *Circ Cardiovasc Qual Outcomes* 2009; **2**: 533–539. doi:10.1161/CIRCOUTCOMES.109.848259.
36. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. *Circ Res* 2011; **108**: 1392–1412. doi:10.1161/CIRCRESAHA.110.234138.
37. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. *Arthritis Res Ther* 2007; **9**(Suppl 1): S1. doi:10.1186/ar2165.
38. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. *Nature* 2005; **437**: 270–274. doi:10.1038/nature03940.
39. Chen JH, Simmons CA. Cell–matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. *Circ Res* 2011; **108**: 1510–1524. doi:10.1161/CIRCRESAHA.110.234237.
40. Yao Y, Bennett BJ, Wang X, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. *Circ Res* 2010; **107**: 485–494. doi:10.1161/CIRCRESAHA.110.219071.
41. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. *Thromb Haemost* 2009; **101**: 706–713.
42. Schinke T, Amendt C, Trinkl A, et al. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. *J Biol Chem* 1996; **271**: 20789–20796.
43. Avila-Diaz M, Mora-Villalpando C, Prado-Urbe MC, et al. De novo development of heart valve calcification in incident peritoneal dialysis patients. *Arch Med Res* 2013; **44**: 638–644. doi:10.1016/j.arcmed.2013.10.015.
44. Ix JH, Chertow GM, Shlipak MG, et al. Association of fetuin-a with mitral annular calcification and aortic stenosis among persons with coronary heart disease data from the heart and soul study. *Circulation* 2007; **115**: 2533–2539.
45. Yu PJ, Skolnick A, Ferrari G, et al. Correlation between plasma osteopontin levels and aortic valve calcification: potential insights into the pathogenesis of aortic valve calcification and stenosis. *J Thorac Cardiovasc Surg* 2009; **138**: 196–199. doi:10.1016/j.jtcvs.2008.10.045.
46. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. *Circulation* 2003; **107**: 2181–2184. doi:10.1161/01.CIR.0000070591.21548.69.
47. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. *J Am Coll Cardiol* 2006; **47**: 1707–1712. doi:10.1016/j.jacc.2006.02.040.
48. Karsenty G, Ducy P, Starbuck M, et al. Cbfa1 as a regulator of osteoblast differentiation and function. *Bone* 1999; **25**: 107–108.
49. Gehron Robey P, Boskey AL. The biochemistry of bone. In *Osteoporosis*, Marcus R, Feldman D (eds.). Raven Press: New York; 1996, 95–184.
50. Mohler ER, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. *Circulation* 2001; **103**: 1522–1528.
51. Shimizu T, Tanaka T, Iso T, et al. Notch signaling pathway enhances bone morphogenetic protein 2 (BMP2) responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells. *J Biol Chem* 2011; **286**: 19138–19148. doi:10.1074/jbc.M110.175786.



52. White MP, Theodoris CV, Liu L, *et al.* NOTCH1 regulates matrix gla protein and calcification gene networks in human valve endothelium. *J Mol Cell Cardiol* 2015; **84**: 13–23. doi:10.1016/j.jmcc.2015.04.006.
53. Aikawa E, Otto CM. Look more closely at the valve imaging calcific aortic valve disease. *Circulation* 2012; **125**: 9–11. doi:10.1161/circulationaha.111.073452.
54. O'Brien KD, Reichenbach DD, Marcovina SM, *et al.* Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. *Arterioscler Thromb Vasc Biol* 1996; **16**: 523–532.
55. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. *Arterioscler Thromb Vasc Biol* 1999; **19**: 1218–1222.
56. Parhami F, Morrow AD, Balucan J, *et al.* Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. *Arterioscler Thromb Vasc Biol* 1997; **17**: 680–687.
57. Mazzone A, Epistolato MC, De Caterina R, *et al.* Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. *J Am Coll Cardiol* 2004; **43**: 1670–1676. doi:10.1016/j.jacc.2003.12.041.
58. Akahori H, Tsujino T, Naito Y, *et al.* Intraleaflet haemorrhage is associated with rapid progression of degenerative aortic valve stenosis. *Eur Heart J* 2011; **32**: 888–896. doi:10.1093/eurheartj/ehq479.
59. Butcher JT, Penrod AM, Garcia AJ, *et al.* Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. *Arterioscler Thromb Vasc Biol* 2004; **24**: 1429–1434. doi:10.1161/01.ATV.0000130462.50769.5a.
60. Butcher JT, Nerem RM. Porcine aortic valve interstitial cells in three-dimensional culture: comparison of phenotype with aortic smooth muscle cells. *J Heart Valve Dis* 2004; **13**: 478–485.
61. Sider KL, Zhu C, Kwong AV, *et al.* Evaluation of a porcine model of early aortic valve sclerosis. *Cardiovasc Pathol* 2014; **23**: 289–297. doi:10.1016/j.carpath.2014.05.004.
62. Mohler ER, Chawla MK, Chang AW, *et al.* Identification and characterization of calcifying valve cells from human and canine aortic valves. *J Heart Valve Dis* 1999; **8**: 254–260.
63. Moghadasian MH, Frohlich JJ, McManus BM. Advances in experimental dyslipidemia and atherosclerosis. *Lab Invest* 2001a; **81**: 1173–1183. doi:10.1038/labinvest.3780331.
64. Moghadasian MH. Experimental atherosclerosis—a historical overview. *Life Sci* 2002; **70**: 855–865. doi:10.1016/s0024-3205(01)01479-5.
65. Guerraty M, Mohler ER, III. Models of aortic valve calcification. *J Invest Med* 2007; **55**: 278–283. doi:10.2310/6650.2007.00012.
66. Sider KL, Blaser MC, Simmons CA. Animal models of calcific aortic valve disease. *Int J Inflam* 2011; (2011364310). doi:10.4061/2011/364310.
67. Johnson CM, Fass DN. Porcine cardiac valvular endothelial cells in culture. A relative deficiency of fibronectin synthesis in vitro. *Lab Invest* 1983; **49**: 589–598.
68. Manduteanu I, Popov D, Radu A, *et al.* Calf cardiac valvular endothelial cells in culture: production of glycosaminoglycans, prostacyclin and fibronectin. *J Mol Cell Cardiol* 1988; **20**: 103–118.
69. Paranya G, Vineberg S, Dvorin E, *et al.* Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. *Am J Pathol* 2001; **159**: 1335–1343.
70. Messier RH, Bass BL, Aly HM, *et al.* Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. *J Surg Res* 1994; **57**: 1–21. doi:10.1006/jsre.1994.1102.
71. Johnson CM, Hanson MN, Helgeson SC. Porcine cardiac valvular subendothelial cells in culture: cell isolation and growth characteristics. *J Mol Cell Cardiol* 1987; **19**: 1185–1193.
72. Yperman J, De Visscher G, Holvoet P, *et al.* Molecular and functional characterization of ovine cardiac valve-derived interstitial cells in primary isolates and cultures. *Tissue Eng* 2004; **10**: 1368–1375. doi:10.1089/ten.2004.10.1368.
73. Butcher JT, Nerem RM. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. *Tissue Eng* 2006; **12**: 905–915. doi:10.1089/ten.2006.12.905.
74. Cuniberti LA, Stutzbach PG, Guevara E, *et al.* Development of mild aortic valve stenosis in a rabbit model of hypertension. *J Am Coll Cardiol* 2006; **47**: 2303–2309. doi:10.1016/j.jacc.2005.12.070.
75. Skold BH, Getty R, Ramsey FK. Spontaneous atherosclerosis in the arterial system of aging swine. *Am J Vet Res* 1966; **27**: 257–273.
76. Dixon JL, Stoops JD, Parker JL, *et al.* Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. *Arterioscler Thromb Vasc Biol* 1999; **19**: 2981–2992.
77. Gerrity RG, Natarajan R, Nadler JL, *et al.* Diabetes-induced accelerated atherosclerosis in swine. *Diabetes* 2001; **50**: 1654–1665.
78. Simmons CA, Grant GR, Manduchi E, *et al.* Spatial heterogeneity of endothelial phenotypes correlates with site-specific vulnerability to calcification in normal porcine aortic valves. *Circ Res* 2005; **96**: 792–799. doi:10.1161/01.RES.0000161998.92009.64.
79. Viaene L, Behets GJ, Claes K, *et al.* Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? *Nephrol Dial Transplant* 2013. doi:10.1093/ndt/gf039.
80. Warnock JN, Nanduri B, Pregonero Gamez CA, *et al.* Gene profiling of aortic valve interstitial cells under elevated pressure conditions: modulation of inflammatory gene networks. *Int J Inflam* 2011; **2011**: 176412. DOI: 10.4061/2011/176412
81. Cowell SJ, Newby DE, Prescott RJ, *et al.* A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* 2005; **352**: 2389–2397. doi:10.1056/NEJMoa043876.
82. Rossebø AB, Pedersen TR, Boman K, *et al.* Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* 2008; **359**: 1343–1356. doi:10.1056/NEJMoa0804602.
83. Chan KL, Teo K, Dumesnil JG, *et al.* Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. *Circulation* 2010; **121**: 306–314. doi:10.1161/CIRCULATIONAHA.109.900027.
84. Giachelli CM. Vascular calcification mechanisms. *J Am Soc Nephrol* 2004; **15**: 2959–2964. doi:10.1097/01.ASN.0000145894.57533.C4.
85. Li XW, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. *Circ Res* 2006; **98**: 905–912. doi:10.1161/01.RES.0000216409.20863.e7.
86. Zhu D, Mackenzie NC, Farquharson C, *et al.* Mechanisms and clinical consequences of vascular calcification. *Front Endocrinol (Lausanne)* 2012; **3**: 95. doi:10.3389/fendo.2012.00095.
87. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vasc Biol* 2004; **24**: 1161–1170. doi:10.1161/01.ATV.0000133194.94939.42.
88. Towler DA. Vascular calcification: a perspective on an imminent disease epidemic. *IBMS BoneKey* 2008; **5**: 41–58. doi:10.1138/20080298.
89. Oliveira RB, Okazaki H, Stinghen AE, *et al.* Vascular calcification in chronic kidney disease: a review. *J Bras Nefrol* 2013; **35**: 147–161. doi:10.5935/0101-2800.20130024.
90. Chen NX, Duan D, O'Neill KD, *et al.* High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. *Nephrol Dial Transplant* 2006; **21**: 3435–3442. doi:10.1093/ndt/gf429.
91. Mackenzie NC, Zhu D, Milne EM, *et al.* Altered bone development and an increase in FGF-23 expression in Enpp1(–/–) mice. *PLoS One* 2012a; **7**: e32177. doi:10.1371/journal.pone.0032177.
92. London GM, Guérin AP, Marchais SJ, *et al.* Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. *Nephrol Dial Transplant* 2003; **18**: 1731–1740.
93. McNally EM. Genetics of vascular calcification. *Circ Res* 2011; **109**: 248–249. doi:10.1161/RES.0b013e31822a19fe.
94. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. *Cardiovasc Pathol* 2004; **13**: 63–70. doi:10.1016/S1054-8807(03)00130-3.



95. Shroff RC, Shanahan CM. The vascular biology of calcification. *Semin Dialysis* 2007; **20**: 103–109. doi:10.1111/j.1525-139X.2007.00255.x.
96. Demer LL, Tintut Y. Vascular calcification—pathobiology of a multifaceted disease. *Circulation* 2008; **117**: 2938–2948. doi:10.1161/circulationaha.107.743161.
97. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. *Circulation* 1995; **91**: 2488–2496.
98. Frink RJ. *Inflammatory Atherosclerosis: Characteristics of the Injurious Agent*. Heart Research Foundation: Sacramento, Calif., 2002.
99. Kim KM. Calcification of matrix vesicles in human aortic valve and aortic media. *Fed Proc* 1976; **35**: 156–162.
100. Tanimura A, McGregor DH, Anderson HC. Calcification in atherosclerosis. I. Human studies. *J Exp Pathol* 1986; **2**: 261–273.
101. Boström K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. *J Clin Invest* 1993; **91**: 1800–1809. doi:10.1172/JCI116391.
102. Fitzpatrick LA, Severson A, Edwards WD, et al. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. *J Clin Invest* 1994; **94**: 1597–1604. doi:10.1172/JCI117501.
103. Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. *J Clin Invest* 1993; **92**: 1686–1696. doi:10.1172/JCI116755.
104. Hirota S, Imakita M, Kohri K, et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. *Am J Pathol* 1993; **143**: 1003–1008.
105. Shanahan CM, Cary NR, Metcalfe JC, et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. *J Clin Invest* 1994; **93**: 2393–2402. doi:10.1172/JCI117246.
106. Dore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. *Arterioscler Thromb Vasc Biol* 2001; **21**: 1998–2003.
107. de Kreutzenberg SV, Fadini GP, Guzzinati S, et al. Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. *Diabetes Care* 2015; **38**: 1937–1944.
108. Vengrenyuk Y, Carlier S, Xanthos S, et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. *Proc Natl Acad Sci U S A* 2006; **103**: 14678–14683. doi:10.1073/pnas.0606310103.
109. Bluestein D, Alemu Y, Avrahami I, et al. Influence of microcalcifications on vulnerable plaque mechanics using FSI modeling. *J Biomech* 2008; **41**: 1111–1118. doi:10.1016/j.jbiomech.2007.11.029.
110. Wenk JF, Papadopoulos P, Zohdi TI. Numerical modeling of stress in stenotic arteries with microcalcifications: a micromechanical approximation. *J Biomech Eng* 2010; **132**: 091011. doi:10.1115/1.4001351.
111. Cheng GC, Loree HM, Kamm RD, et al. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. *Circulation* 1993; **87**: 1179–1187.
112. Huang H, Virmani R, Younis H, et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. *Circulation* 2001; **103**: 1051–1056.
113. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. *Kidney Int* 2004; **66**: 2293–2299. doi:10.1111/j.1523-1755.2004.66015.x.
114. Giachelli CM. The emerging role of phosphate in vascular calcification. *Kidney Int* 2009; **75**: 890–897. doi:10.1038/ki.2008.644.
115. Zhu D, Mackenzie NC, Millán JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. *PLoS One* 2011; **6**: e19595. doi:10.1371/journal.pone.0019595.
116. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. *Circ Res* 2001; **89**: 1147–1154.
117. Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. *Circ Res* 2009; **104**: 733–741. doi:10.1161/CIRCRESAHA.108.183053.
118. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. *Circ Res* 2011; **109**: 578–592. doi:10.1161/CIRCRESAHA.111.247965.
119. Schäfer C, Heiss A, Schwarz A, et al. The serum protein  $\alpha_2$ -Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest* 2003; **112**: 357–366.
120. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature* 1997; **386**: 78–81.
121. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes Dev* 1998; **12**: 1260–1268.
122. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. *Arterioscler Thromb Vasc Biol* 1998; **18**: 1400–1407. doi:10.1161/01.atv.18.9.1400.
123. Sancho J, Duh Q, Oms L, et al. A new experimental model for secondary hyperparathyroidism. *Surgery* 1989; **106**: 1002–1008.
124. Vercauteren SR, Ysebaert DK, De Greef KE, et al. Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. *J Am Soc Nephrol* 1999; **10**: 2551–2561.
125. Koleganova N, Piecha G, Ritz E, et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. *Kidney Int* 2009; **75**: 60–71.
126. Mizobuchi M, Ogata H, Hatamura I, et al. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. *Nephrol Dial Transplant* 2006; **21**: 911–916. doi:10.1093/ndt/gfk008.
127. Mizobuchi M, Finch J, Martin D, et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. *Kidney Int* 2007; **72**: 709–715.
128. Lopez I, Mendoza F, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. *Kidney Int* 2008; **73**: 300–307.
129. Haffner D, Hoher B, Müller D, et al. Systemic cardiovascular disease in uremic rats induced by 1, 25 (OH) 2D3. *J Hypertens* 2005; **23**: 1067–1075.
130. Yokozawa T, Zheng PD, Oura H, et al. Animal model of adenine-induced chronic renal failure in rats. *Nephron* 1986; **44**: 230–234.
131. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. *Kidney Int* 2003; **64**: 441–450.
132. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. *Nat Genet* 2003; **34**: 379–381. doi:10.1038/ng1221.
133. Levy-Litan V, Herskovitz E, Avizov L, et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. *Am J Hum Genet* 2010; **86**: 273–278. doi:10.1016/j.ajhg.2010.01.010.
134. Lorenz-Depiereux B, Schnabel D, Tiosano D, et al. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. *Am J Hum Genet* 2010; **86**: 267–272. doi:10.1016/j.ajhg.2010.01.006.
135. Nitschke Y, Baujat G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. *Am J Hum Genet* 2012; **90**: 25–39. doi:10.1016/j.ajhg.2011.11.020.
136. Rutsch F, Vaingankar S, Johnson K, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. *Am J Pathol* 2001; **158**: 543–554. doi:10.1016/S0002-9440(10)63996-X.
137. Mackenzie NC, Huesa C, Rutsch F, et al. New insights into ENPP1 function: lessons from clinical and animal studies. *Bone* 2012b; **51**: 961–968. doi:10.1016/j.bone.2012.07.014.
138. Cranley JJ. Focal medial calcification of the pulmonary artery: a survey of 1066 horses. *Equine Vet J* 1983; **15**: 278–280.

139. Imaizumi K, Nakamura T, Kiryu K, *et al.* Morphological changes of the aorta and pulmonary artery in thoroughbred racehorses. *J Comp Pathol* 1989; **101**: 1–9.
140. Nakamura T, Kiryu K, Machida N, *et al.* Histologic features of the carotid artery trifurcation in thoroughbreds. *Am J Vet Res* 1992; **53**: 288–290.
141. Arroyo LG, Hayes MA, Delay J, *et al.* Arterial calcification in race horses. *Vet Pathol* 2008; **45**: 617–625. doi:10.1354/vp.45-5-617.
142. Huesa C, Staines KA, Millan L, *et al.* Effects of etidronate on the Enpp1(–/–) mouse model of generalized arterial calcification of infancy. *Int J Mol Med* 2015; **36**: 159–165. doi:10.3892/ijmm.2015.2212.
143. Russell RG. Bisphosphonates: the first 40 years. *Bone* 2011; **49**: 2–19. doi:10.1016/j.bone.2011.04.022.
144. Otero JE, Gottesman GS, McAlister WH, *et al.* Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. *J Bone Miner Res* 2013; **28**: 419–430. doi:10.1002/jbmr.1752.
145. Albright RA, Stabach P, Cao W, *et al.* ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. *Nat Commun* 2015; **6**: 10006. doi:10.1038/ncomms10006.
146. Bunton TE, Biery NJ, Myers L, *et al.* Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. *Circ Res* 2001; **88**: 37–43.
147. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. *J Cell Biol* 1986; **103**: 2499–2509.
148. Quondamatteo F, Reinhardt DP, Charbonneau NL, *et al.* Fibrillin-1 and fibrillin-2 in human embryonic and early fetal development. *Matrix Biol* 2002; **21**: 637–646.
149. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. *Circulation* 2005; **111**: e150–e157. doi:10.1161/01.CIR.0000155243.70456.F4.
150. Groenink M, den Hartog AW, Franken R, *et al.* Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J* 2013; **34**: 3491–3500. doi:10.1093/eurheartj/ehz334.
151. Potter KA, Besser TE. Cardiovascular lesions in bovine Marfan syndrome. *Vet Pathol* 1994; **31**: 501–509.
152. Besser TE, Potter KA, Bryan GM, *et al.* An animal model of the Marfan syndrome. *Am J Med Genet* 1990; **37**: 159–165. doi:10.1002/ajmg.1320370137.
153. Singleton AC, Mitchell AL, Byers PH, *et al.* Bovine model of Marfan syndrome results from an amino acid change (c.3598G>A, p. E1200K) in a calcium-binding epidermal growth factor-like domain of fibrillin-1. *Hum Mutat* 2005; **25**: 348–352. doi:10.1002/humu.20152.
154. Potter KA, Hoffman Y, Sakai LY, *et al.* Abnormal fibrillin metabolism in bovine Marfan syndrome. *Am J Pathol* 1993; **142**: 803–810.
155. Hirano T, Matsuhashi T, Kobayashi N, *et al.* Identification of an FBN1 mutation in bovine Marfan syndrome-like disease. *Anim Genet* 2012; **43**: 11–17. doi:10.1111/j.1365-2052.2011.02209.x.
156. Rezz R, Barreto FC, Barreto DV, *et al.* Inhibitors of vascular calcification as potential therapeutic targets. *J Nephrol* 2011; **24**: 416–427. doi:10.5301/JN.2011.8420.
157. Pereira L, Andrikopoulos K, Tian J, *et al.* Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. *Nat Genet* 1997; **17**: 218–222. doi:10.1038/ng1097-218.
158. Sugitani H, Wachi H, Mecham RP, *et al.* Accelerated calcification represses the expression of elastic fiber components and lysyl oxidase in cultured bovine aortic smooth muscle cells. *J Atheroscler Thromb* 2002; **9**: 292–298.
159. Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. *Am J Cardiol* 1984; **53**: 849–855.
160. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. *Circulation* 2005; **111**: 920–925. doi:10.1161/01.CIR.0000155623.48408.C5.
161. Mohamed SA, Aherrahrou Z, Liptau H, *et al.* Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. *Biochem Biophys Res Commun* 2006; **345**: 1460–1465. doi:10.1016/j.bbrc.2006.05.046.
162. McKellar SH, Tester DJ, Yagubyan M, *et al.* Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. *J Thorac Cardiovasc Surg* 2007; **134**: 290–296. doi:10.1016/j.jtcvs.2007.02.041.
163. Siu SC, Silversides CK. Bicuspid aortic valve disease. *J Am Coll Cardiol* 2010; **55**: 2789–2800. doi:10.1016/j.jacc.2009.12.068.
164. Laforest B, Nemer M. Genetic insights into bicuspid aortic valve formation. *Cardiol Res Pract* 2012; 2012: 180297. DOI: 10.1155/2012/180297
165. Nataatmadja M, West M, West J, *et al.* Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. *Circulation* 2003; **108**(Suppl 1): II329–II334. doi:10.1161/01.cir.0000087660.82721.15.
166. Getz GS, Reardon CA. Animal models of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2012; **32**: 1104–1115. doi:10.1161/atvbaha.111.237693.
167. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999; **340**: 115–126. doi:10.1056/NEJM199901143400207.
168. Hines TG, Jacobson NL, Beitz DC, *et al.* Dietary calcium and vitamin D: risk factors in the development of atherosclerosis in young goats. *J Nutr* 1985; **115**: 167–178.
169. Kumar V, Abbas AK, Aster JC. *Robbins Basic Pathology*. Elsevier Health Sciences: Philadelphia, Pa., 2012.
170. Hall JE. *Guyton and Hall Textbook of Medical Physiology*. Elsevier Health Sciences, 2015.
171. Davies PF, Remuzzi A, Gordon EJ, *et al.* Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. *Proc Natl Acad Sci U S A* 1986; **83**: 2114–2117.
172. Back M, Bu DX, Branstrom R, *et al.* Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. *Proc Natl Acad Sci USA* 2005; **102**: 17501–17506.
173. Kannel WB, Castelli WP, Gordon T, *et al.* Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. *Ann Intern Med* 1971; **74**: 1–12.
174. Rosengren A, Eriksson H, Larsson B, *et al.* Secular changes in cardiovascular risk factors over 30 years in Swedish men aged 50: the study of men born in 1913, 1923, 1933 and 1943. *J Intern Med* 2000; **247**: 111–118.
175. Daida H, Teramoto T, Kitagawa Y, *et al.* The relationship between low-density lipoprotein cholesterol levels and the incidence of cardiovascular disease in high-risk patients treated with pravastatin: main results of the APPROACH-J study. *Int Heart J* 2014; **55**: 39–47.
176. Kapourchali FR, Surendiran G, Chen L, *et al.* Animal models of atherosclerosis. *World J Clin Cases*: WJCC 2014; **2**: 126–132. DOI: 10.12998/wjcc.v2.i5.126
177. Barter PJ, Brewer HB, Jr, Chapman MJ, *et al.* Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. *Arterioscler Thromb Vasc Biol* 2003; **23**: 160–167.
178. Mahley R. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 1988; **240**: 622–630. doi:10.1126/science.3283935.
179. Breslow JL, Zannis VI, SanGiacomo TR, *et al.* Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. *J Lipid Res* 1982; **23**: 1224–1235.
180. Feussner G, Feussner V, Hoffmann MM, *et al.* Molecular basis of type III hyperlipoproteinemia in Germany. *Hum Mutat* 1998; **11**: 417–423. doi:10.1002/(sici)1098-1004(1998)11:6<417::aid-humu1>3.0.co;2-5.
181. Civeira F, Pocovi M, Cenarro A, *et al.* Apo E variants in patients with type III hyperlipoproteinemia. *Atherosclerosis* 1996; **127**: 273–282.
182. Wouters K, Shiri-Sverdlov R, van Gorp PJ, *et al.* Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. *Clin Chem Lab Med* 2005; **43**: 470–479.

183. Zadelaar S, Kleemann R, Verschuren L, *et al.* Mouse models for atherosclerosis and pharmaceutical modifiers. *Arterioscler Thromb Vasc Biol* 2007; **27**: 1706–1721. doi:10.1161/atvbaha.107.142570.
184. Davignon J. Apolipoprotein E and Atherosclerosis: Beyond Lipid Effect. *Arterioscler Thromb Vasc Biol* 2005; **25**: 267–269. DOI: 10.1161/01.ATV.0000154570.50696.2c
185. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. *Arterioscler Thromb Vasc Biol* 2005; **25**: 436–441. doi:10.1161/01.atv.0000152613.83243.12.
186. Ali K, Middleton M, Puré E, *et al.* Apolipoprotein E suppresses the type I inflammatory response in vivo. *Circ Res* 2005; **97**: 922–927. doi:10.1161/01.res.0000187467.67684.43.
187. Tenger C, Zhou X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. *Immunology* 2003; **109**: 392–397. doi:10.1046/j.1365-2567.2003.01665.x.
188. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *J Clin Invest* 2003; **111**: 1795–1803. doi:10.1172/JCI200318925.
189. Hobbs HH, Russell DW, Brown MS, *et al.* The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. *Annu Rev Genet* 1990; **24**: 133–170.
190. Powell-Braxton L, Veniant M, Latvala RD, *et al.* A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. *Nat Med* 1998; **4**: 934–938.
191. Sanan DA, Newland DL, Tao R, *et al.* Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(A). *Proc Natl Acad Sci* 1998; **95**: 4544–4549.
192. Fenning RS, Burgert ME, Hamamdizic D, *et al.* Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2. *J Am Heart Assoc* 2015; **4**. doi:10.1161/jaha.114.001477.
193. Hayashi K, Mani V, Nemade A, *et al.* Variations in atherosclerosis and remodeling patterns in aorta and carotids. *J Cardiovasc Magn Reson* 2010; **12**: 10. doi:10.1186/1532-429x-12-10.
194. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, *et al.* Animal models of cardiovascular diseases. *J Biomed Biotechnol* 2011; **2011**. doi:10.1155/2011/497841.
195. Moghadasian MH, McManus BM, Nguyen LB, *et al.* Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. *FASEB J* 2001b; **15**: 2623–2630. doi:10.1096/fj.01-0463com.
196. Anderson L. *Laboratory Animal Medicine*. Elsevier Academic Press: Oxford, 2015.
197. Skold BH, Jacobson NL, Getty R. Spontaneous atherosclerosis of bovine. *J Dairy Sci* 1967; **50**: 1712–1714. doi:10.3168/jds.S0022-0302(67)87700-2.
198. Stout C, Bohorquez F. Aortic atherosclerosis in hoofed mammals. *J Atheroscler Res* 1969; **9**: 73–80.
199. Gupta PP, Nagpal SK. Spontaneous aortic atherosclerosis in sheep. *Vet Pathol* 1979; **16**: 548–552.
200. Gupta PP. Spontaneous aortic atherosclerosis in cattle. *Zentralbl Veterinarmed A* 1980; **27**: 143–151.
201. Wiggers KD, Jacobson NL, Getty R, *et al.* Mode of cholesterol ingestion and atherosclerosis in young bovine. *Atherosclerosis* 1973; **17**: 281–295. doi:10.1016/0021-9150(73)90094-4.
202. Kenealy MD, Jacobson NL, Wiggers KD. Effects of supplemental dietary cholesterol and exercise on blood cholesterol and atherosclerosis in goat. *Atherosclerosis* 1977; **27**: 65–69. doi:10.1016/0021-9150(77)90025-9.
203. Turk JR, Laughlin MH. Physical activity and atherosclerosis: which animal model? *Can J Appl Physiol-Revue Can De Physiol Appl* 2004; **29**: 657–683.
204. Turk JR, Henderson KK, Vanvickle GD, *et al.* Arterial endothelial function in a porcine model of early stage atherosclerotic vascular disease. *Int J Exp Pathol* 2005; **86**: 335–345. doi:10.1111/j.0959-9673.2005.00446.x.
205. Simmons GH, Padilla J, Jenkins NT, *et al.* Exercise training and vascular cell phenotype in a swine model of familial hypercholesterolemia: conduit arteries and veins. *Exp Physiol* 2014; **99**: 454–465. doi:10.1113/expphysiol.2013.075838.
206. Reiser R, Sorrels MF, Williams MC. Influence of high levels of dietary fats and cholesterol on atherosclerosis and lipid distribution in swine. *Circ Res* 1959; **7**: 833–846. doi:10.1161/01.res.7.6.833.
207. Koskinas KC, Feldman CL, Chatzizisis YS, *et al.* Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress a serial, in vivo intravascular ultrasound study. *Circulation* 2010; **121**: 2092–2101.
208. Casani L, Sanchez-Gomez S, Vilahur G, *et al.* Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. *Thromb Haemost* 2005; **94**: 1035–1041.
209. Gal D, Chokshi S, Mosseri M, *et al.* Percutaneous delivery of low-level laser energy reverses histamine-induced spasm in atherosclerotic Yucatan microswine. *Circulation* 1992; **85**: 756–768.
210. White FC, Carroll SM, Magnet A, *et al.* Coronary collateral development in swine after coronary artery occlusion. *Circ Res* 1992a; **71**: 1490–1500.
211. Sturek M, Dixon JL, Stoops JD, *et al.* Accelerated atherosclerosis in a porcine model of diabetic dyslipidemia. *Diabetes (supplement)* 1998; **47**: A1161.
212. Bellinger DA, Merricks EP, Nichols TC. Swine models of type 2 diabetes mellitus: insulin resistance, glucose tolerance, and cardiovascular complications. *ILAR J* 2006; **47**: 243–258. doi:10.1093/ilar.47.3.243.
213. Ebrahim S, Papacosta O, Whincup P, *et al.* Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. *Stroke* 1999; **30**: 841–850.
214. Cerne A, Kranjec I. Atherosclerotic burden in coronary and peripheral arteries in patients with first clinical manifestation of coronary artery disease. *Heart Vessels* 2002; **16**: 217–226. doi:10.1007/s003800200028.
215. Lacroix P, Aboyans V, Espaliat E, *et al.* Carotid intima-media thickness as predictor of secondary events after coronary angioplasty. *Int Angiol* 2003; **22**: 279–283.
216. van der Meer IM, Bots ML, Hofman A, *et al.* Predictive value of non-invasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. *Circulation* 2004; **109**: 1089–1094. doi:10.1161/01.CIR.0000120708.59903.1B.
217. Cheng KS, Mikhailidis DP, Hamilton G, *et al.* A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. *Cardiovasc Res* 2002; **54**: 528–538.
218. Prescott MF, McBride C, Hasler-Rapacz J, *et al.* Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterol bearing mutant alleles for apolipoprotein B. *Am J Pathol* 1991; **139**: 139–147.
219. Prescott MF, Hasler-Rapacz J, Linden-Reed J, *et al.* Familial hypercholesterolemia associated with coronary atherosclerosis in swine bearing different alleles for apolipoprotein B. *Ann N Y Acad Sci* 1994; **748**: 283–292.
220. Hasler-Rapacz J, Ellegren H, Fridolfsson AK, *et al.* Identification of a mutation in the low density lipoprotein receptor gene associated with recessive familial hypercholesterolemia in swine. *Am J Med Genet* 1998; **76**: 379–386.
221. Grunwald KAA, Schueler K, Uelmen PJ, *et al.* Identification of a novel Arg → Cys mutation in the LDL receptor that contributes to spontaneous hypercholesterolemia in pigs. *J Lipid Res* 1999; **40**: 475–485.
222. Agarwala A, Billheimer J, Rader DJ. Mighty minipig in fight against cardiovascular disease. *Sci Transl Med* 2013; **5**: 166fs161. doi:10.1126/scitranslmed.3005369.
223. Al-Mashhadi RH, Sørensen CB, Kragh PM, *et al.* Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. *Sci Transl Med* 2013; **5**: 166ra161. doi:10.1126/scitranslmed.3004853.
224. Edwards JM, Alloosh MA, Long XL, *et al.* Adenosine A1 receptors in neointimal hyperplasia and in-stent stenosis in Ossabaw miniature



- swine. *CoronArtery Dis* 2008; **19**: 27–31. doi:10.1097/MCA.0b013e3282f262b4[doi];00019501-200802000-00005 [pii].
225. Gal D, Isner J. Atherosclerotic Yucatan microswine as a model for novel cardiovascular interventions and imaging. *Swine Model Biomed Res* 1992; **1**: 118–140.
  226. Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery stenosis: analysis and recommendations. On behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thrombosis and Haemostasis of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost* 1999; **81**: 835–843.
  227. Lloyd PG, Sheehy AJ, Edward JM, *et al.* Leukemia inhibitory factor is upregulated in stented coronary arteries of Ossabaw swine. *Coron Artery Dis* 2008; **19**: 217–226.
  228. Lowe HC, Schwartz RS, Mac Neill BD, *et al.* The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents. *Catheter Cardiovasc Interv* 2003; **60**: 515–523. doi:10.1002/ccd.10705.
  229. Sturek M, Alloosh M, Wenzel J, *et al.* Ossabaw Island miniature swine: cardiometabolic syndrome assessment. *Swine Lab: Surg, Anesth, Imaging, and Exp Tech* 2007a; **2**: 397–402.
  230. White C, Ramee S, Banks A, *et al.* The Yucatan miniature swine: an atherogenic model to assess the early potency rates of an endovascular stent. *Swine Model Biomed Res* 1992b: 156–162.
  231. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. *Physiol Res* 2001; **50**: 537–546.
  232. Mansford KR, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. *Lancet* 1968; **1**: 670–671.
  233. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. *Pharmacol Rev* 1970; **22**: 485–518.
  234. King AJF. The use of animal models in diabetes research. *Br J Pharmacol* 2012; **166**: 877–894. doi:10.1111/j.1476-5381.2012.01911.x.
  235. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. *J Clin Invest* 1996; **97**: 1767–1773. doi:10.1172/JCI118604.
  236. Otero P, Bonet B, Herrera E, *et al.* Development of atherosclerosis in the diabetic BALB/c mice: prevention with Vitamin E administration. *Atherosclerosis* 2005; **182**: 259–265. doi:10.1016/j.atherosclerosis.2005.02.024.
  237. Park L, Raman KG, Lee KJ, *et al.* Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. *Nat Med* 1998; **4**: 1025–1031. doi:10.1038/2012.
  238. Calkin AC, Forbes JM, Smith CM, *et al.* Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. *Arterioscler Thromb Vasc Biol* 2005; **25**: 1903–1909. doi:10.1161/01.ATV.0000177813.99577.6b.
  239. Zuccollo A, Shi C, Mastroianni R, *et al.* The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. *Circulation* 2005; **112**: 3001–3008. doi:10.1161/CIRCULATIONAHA.105.581892.
  240. Tse J, Martin-McNauly B, Halks-Miller M, *et al.* Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 $\beta$ -estradiol. *Atherosclerosis* 1999; **144**: 303–313. doi:10.1016/S0021-9150(98)00325-6.
  241. Reaven P, Merat S, Casanada F, *et al.* Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 1997; **17**: 2250–2256.
  242. Otis CR, Wamhoff BR, Sturek M. Hyperglycemia-induced insulin resistance in diabetic dyslipidemic Yucatan swine. *Comp Med* 2003; **53**: 53–64.
  243. Dixon JL, Shen S, Vuchetich JP, *et al.* Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. *J Lipid Res* 2002; **43**: 1618–1629. doi:10.1194/jlr.M200134-JLR200.
  244. Phillips JW, Barringhaus KG, Sanders JM, *et al.* Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. *Circulation* 2003; **108**: 1994–1999. doi:10.1161/01.cir.0000092886.52404.50.
  245. Collins AR, Meehan WP, Kintscher U, *et al.* Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. *Arterioscler Thromb Vasc Biol* 2001; **21**: 365–371. doi:10.1161/01.atv.21.3.365.
  246. Kennedy AJ, Ellacott KLJ, King VL, *et al.* Mouse models of the metabolic syndrome. *Dis Model Mech* 2010; **3**: 156–166. doi:10.1242/dmm.003467.
  247. Hasty AH, Shimano H, Osuga J, *et al.* Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. *J Biol Chem* 2001; **276**: 37402–37408. doi:10.1074/jbc.M010176200.
  248. Mertens A, Verhamme P, Bielicki JK, *et al.* Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. *Circulation* 2003; **107**: 1640–1646. doi:10.1161/01.cir.0000056523.08033.9f.
  249. Verreth W, De Keyser D, Pelat M, *et al.* Weight-loss-associated induction of peroxisome proliferator-activated receptor- $\alpha$  and peroxisome proliferator-activated receptor- $\gamma$  correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. *Circulation* 2004; **110**: 3259–3269. doi:10.1161/01.cir.0000147614.85888.7a.
  250. Hasty AH, Gruen ML, Terry ES, *et al.* Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model. *J Nutr Biochem* 2007; **18**: 127–133. doi:10.1016/j.jnutbio.2006.03.012.
  251. Verreth W, Ganame J, Mertens A, *et al.* Peroxisome proliferator-activated receptor- $\alpha$ ,  $\gamma$ -agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. *Arterioscler Thromb Vasc Biol* 2006; **26**: 922–928. doi:10.1161/01.ATV.0000207318.42066.bb.
  252. Gruen ML, Saraswathi V, Nuotio-Antar AM, *et al.* Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. *Atherosclerosis* 2006; **186**: 54–64. doi:10.1016/j.atherosclerosis.2005.07.007.
  253. Wu KK, Wu TJ, Chin J, *et al.* Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. *Atherosclerosis* 2005; **181**: 251–259. doi:10.1016/j.atherosclerosis.2005.01.029.
  254. Wendt T, Harja E, Bucciarelli L, *et al.* RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. *Atherosclerosis* 2006; **185**: 70–77. doi:10.1016/j.atherosclerosis.2005.06.013.
  255. Atkinson RD, Coenen KR, Plummer MR, *et al.* Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice. *Am J Physiol Endocrinol Metab* 2008; **294**: E284–E290. doi:10.1152/ajpendo.00601.2007.
  256. Goldberg IJ. Why does diabetes increase atherosclerosis? I don't know!. *J Clin Invest* 2004; **114**: 613–615. doi:10.1172/JCI200422826.
  257. Martin RJ, Gobble JL, Hartsock TH, *et al.* Characterization of an obese syndrome in the pig. *Proc Soc Exp Biol Med* 1973; **143**: 198–203.
  258. Neeb ZP, Edwards JM, Alloosh M, *et al.* Metabolic syndrome and coronary artery disease in ossabaw compared with yucatan swine. *Comp Med* 2010; **60**: 300–315.
  259. Edwards JM, Neeb ZP, Alloosh MA, *et al.* Exercise training decreases store-operated Ca<sup>2+</sup> entry associated with metabolic syndrome and coronary atherosclerosis. *Cardiovasc Res* 2010; **85**: 631–640. doi:10.1093/cvr/cvp308.
  260. Sturek M, Alloosh M, Wenzel J, *et al.* 2007b. Ossabaw Island miniature swine: cardiometabolic syndrome assessment. In *Swine in the Laboratory: Surgery, Anesthesia, Imaging, and Experimental Techniques*, Swindle MM (ed.). CRC Press: Boca Raton; 397–402.
  261. Dyson MC, Alloosh M, Vuchetich JP, *et al.* Components of metabolic syndrome and coronary artery disease in female Ossabaw swine fed excess atherogenic diet. *Comp Med* 2006; **56**: 35–45.



262. Trollope A, Moxon JV, Moran CS, *et al.* Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. *Cardiovasc Pathol* 2011; **20**: 114–123. doi:10.1016/j.carpath.2010.01.001.
263. Riches K, Angelini TG, Mudhar GS, *et al.* Exploring smooth muscle phenotype and function in a bioreactor model of abdominal aortic aneurysm. *J Transl Med* 2013; **11**: 208. doi:10.1186/1479-5876-11-208.
264. Khan S, Verma V, Verma S, *et al.* Assessing the potential risk of rupture of abdominal aortic aneurysms. *Clin Radiol* 2015; **70**: 11–20. doi:10.1016/j.crad.2014.09.016.
265. Frydman G, Walker PJ, Summers K, *et al.* The value of screening in siblings of patients with abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg* 2003; **26**: 396–400.
266. Nordon IM, Hinchliffe RJ, Loftus IM, *et al.* Pathophysiology and epidemiology of abdominal aortic aneurysms. *Nat Rev Cardiol* 2011; **8**: 92–102. doi:10.1038/nrcardio.2010.180.
267. Klocke R, Tian W, Kuhlmann MT, *et al.* Surgical animal models of heart failure related to coronary heart disease. *Cardiovasc Res* 2007; **74**: 29–38. doi:10.1016/j.cardiores.2006.11.026.
268. Townsend N, Williams J, Bhatnagar P, *et al.* *Cardiovascular Disease Statistics 2014*. British Heart Foundation: London, UK, 2014.
269. Schwartz RS, Murphy JG, Edwards WD, *et al.* Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. *Circulation* 1990; **82**: 2190–2200.
270. Schwartz RS, Huber KC, Murphy JG, *et al.* Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. *J Am Coll Cardiol* 1992; **19**: 267–274.
271. Bendixen E, Danielsen M, Larsen K, *et al.* Advances in porcine genomics and proteomics—a toolbox for developing the pig as a model organism for molecular biomedical research. *Brief Funct Genomics* 2010; **9**: 208–219. doi:10.1093/bfpg/elq004.
272. Vodicka P, Smetana K, Dvoránková B, *et al.* The miniature pig as an animal model in biomedical research. *Ann N Y Acad Sci* 2005; **1049**: 161–171. doi:10.1196/annals.1334.015.
273. Sanjana NE, Cong L, Zhou Y, *et al.* A transcription activator-like effector toolbox for genome engineering. *Nat Protoc* 2012; **7**: 171–192. doi:10.1038/nprot.2011.431.
274. Urnov FD, Miller JC, Lee YL, *et al.* Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* 2005; **435**: 646–651. doi:10.1038/nature03556.
275. Tesson L, Usal C, Ménoret S, *et al.* Knockout rats generated by embryo microinjection of TALENs. *Nat Biotechnol* 2011; **29**: 695–696. doi:10.1038/nbt.1940.
276. Carlson DF, Tan W, Lillico SG, *et al.* Efficient TALEN-mediated gene knockout in livestock. *Proc Natl Acad Sci U S A* 2012; **109**: 17382–17387. doi:10.1073/pnas.1211446109.
277. Dahlem TJ, Hoshijima K, Jurynek MJ, *et al.* Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. *PLoS Genet* 2012; **8**: e1002861. doi:10.1371/journal.pgen.1002861.
278. Lillico SG, Proudfoot C, Carlson DF, *et al.* Live pigs produced from genome edited zygotes. *Sci Rep* 2013; **3**: 2847. doi:10.1038/srep02847.
279. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 2014; **157**: 1262–1278. doi:10.1016/j.cell.2014.05.010.
280. Ni W, Qiao J, Hu S, *et al.* Efficient gene knockout in goats using CRISPR/Cas9 system. *PLoS One* 2014; **9**: e106718. doi:10.1371/journal.pone.0106718.
281. Reggio BC, James AN, Green HL, *et al.* Cloned transgenic offspring resulting from somatic cell nuclear transfer in the goat: oocytes derived from both follicle-stimulating hormone-stimulated and nonstimulated abattoir-derived ovaries. *Biol Reprod* 2001; **65**: 1528–1533.
282. Hai T, Teng F, Guo R, *et al.* One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. *Cell Res* 2014; **24**: 372–375. doi:10.1038/cr.2014.11.
283. Rubin CJ, Megens HJ, Martinez Barrio A, *et al.* Strong signatures of selection in the domestic pig genome. *Proc Natl Acad Sci U S A* 2012; **109**: 19529–19536. doi:10.1073/pnas.1217149109.
284. Jiang Y, Xie M, Chen W, *et al.* The sheep genome illuminates biology of the rumen and lipid metabolism. *Science* 2014; **344**: 1168–1173. doi:10.1126/science.1252806.
285. Hart EA, Caccamo M, Harrow JL, *et al.* Lessons learned from the initial sequencing of the pig genome: comparative analysis of an 8 Mb region of pig chromosome 17. *Genome Biol* 2007; **8**: R168. doi:10.1186/gb-2007-8-r168.
286. Rettenberger G, Klett C, Zechner U, *et al.* Visualization of the conservation of synteny between humans and pigs by heterologous chromosomal painting. *Genomics* 1995; **26**: 372–378.
287. Freeman TC, Ivens A, Baillie JK, *et al.* A gene expression atlas of the domestic pig. *BMC Biol* 2012; **10**: 90. doi:10.1186/1741-7007-10-90.
288. Cimini M, Boughner DR, Ronald JA, *et al.* Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. *J Heart Valve Dis* 2005; **14**: 365–375.
289. Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. *J Mol Cell Cardiol* 2009; **47**: 828–834. doi:10.1016/j.yjmcc.2009.08.008.
290. Wada T, McKee MD, Steitz S, *et al.* Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. *Circ Res* 1999; **84**: 166–178.
291. Fischer JW, Steitz SA, Johnson PY, *et al.* Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 2004; **24**: 2391–2396. doi:10.1161/01.ATV.0000147029.63303.28.
292. Wachi H, Sugitani H, Murata H, *et al.* Tropoelastin inhibits vascular calcification via 67-kDa elastin binding protein in cultured bovine aortic smooth muscle cells. *J Atheroscler Thromb* 2004; **11**: 159–166.